An etoposide-resistant subline, SBC-3/ETP, from a human small cell lung cancer cell line, SBC-3, was developed by continuous exposure to increasing concentrations of etoposide in culture. The SBC-3/ETP was 52.1-fold more resistant to etoposide than the parent cell line. The SBC-3/ETP was highly cross-resistant to teniposide, adriamycin, vinca alkaloids, 4-hydroperoxycyclophosphamide, CPT-11 and mitomycin C, and marginally cross-resistant to cisplatin, while the subline showed a collateral sensitivity to bleomycin. Topoisomerase I activity in the SBC-3/ETP was reduced to an extent of one half and topoisomerase II activity to an extent of one eighth in comparison with those of the SBC-3. Intracellular accumulation of [3H]-etoposide in the SBC-3/ETP was significantly lower in comparison to the SBC-3. An overexpression of MDR1 mRNA, and the presence of its product, P-glycoprotein, were detected in the SBC-3/ETP by Northern blotting and flowcytometry using a monoclonal antibody of the protein, MRK16. These results indicate that a decreased activity of topoisomerase II is the major factor for the development of etoposide resistance, and that an overexpression of the MDR1 gene is responsible, in part, for the development of resistance to the drug and some structurally unrelated compounds such as adriamycin and vinca alkaloids.
en-copyright= kn-copyright= en-aut-name=TakigawaNagio en-aut-sei=Takigawa en-aut-mei=Nagio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OhnoshiTaisuke en-aut-sei=Ohnoshi en-aut-mei=Taisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=UeokaHiroshi en-aut-sei=Ueoka en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=KiuraKatsuyuki en-aut-sei=Kiura en-aut-mei=Katsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KimuraIkuro en-aut-sei=Kimura en-aut-mei=Ikuro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University en-keyword=small cell lung cancer kn-keyword=small cell lung cancer en-keyword=etoposide-resistant cell line kn-keyword=etoposide-resistant cell line en-keyword=P-glycoprotein kn-keyword=P-glycoprotein en-keyword=topoisomerase kn-keyword=topoisomerase END start-ver=1.4 cd-journal=joma no-vol=46 cd-vols= no-issue=4 article-no= start-page=249 end-page=256 dt-received= dt-revised= dt-accepted= dt-pub-year=1992 dt-pub=199208 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines. en-subtitle= kn-subtitle= en-abstract= kn-abstract=In an attempt to predict the clinical activity of newly developed anthracycline analogues, ME2303, KRN8602, and SM5887 in the treatment of lung cancer, we compared antitumor activity of these drugs with that of adriamycin, using six human lung cancer cell lines and two drug-resistant human lung cancer sublines. Taking the pharmacokinetic data into consideration, we evaluated the relative antitumor activity: the ratio of area under the concentration-time curve of each drug to the 50% inhibitory concentration of the drug. Regarding this ratio, ME2303 was more potent than adriamycin, SM5887, and KRN8602. Cross-resistance of the new analogues to adriamycin was investigated using an adriamycin-resistant small cell lung cancer subline, SBC-3/ADM100 and an etoposide-resistant subline, SBC-3/ETP. SBC-3/ADM100 being 106-fold more resistant to adriamycin than the parent SBC-3 showed less resistance to the analogues: 1.80-fold to KRN8602, 3.80-fold to SM5887, and 8.60-fold to ME2303. SBC-3/ETP which was 52.1-fold more resistant to etoposide and 39.5-fold more resistant to adriamycin were also less resistant to the new analogues: 3.27-fold to KRN8602, 9.07-fold to SM5887, and 17.3-fold to ME2303. In conclusion, ME2303 was found to be the most potent agent among drugs tested for the treatment of lung cancer, and KRN8602 can be expected to be beneficial for the treatment of drug-resistant small cell lung cancer.
en-copyright= kn-copyright= en-aut-name=TakigawaNagio en-aut-sei=Takigawa en-aut-mei=Nagio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OhnoshiTaisuke en-aut-sei=Ohnoshi en-aut-mei=Taisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=UeokaHiroshi en-aut-sei=Ueoka en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=KiuraKatsuyuki en-aut-sei=Kiura en-aut-mei=Katsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KimuraIkuro en-aut-sei=Kimura en-aut-mei=Ikuro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama Univeristy affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University en-keyword=new anthracycline analogues kn-keyword=new anthracycline analogues en-keyword=ME2303 kn-keyword=ME2303 en-keyword=KRN8602 kn-keyword=KRN8602 en-keyword=SM5887 kn-keyword=SM5887 en-keyword=lung cancer cell line kn-keyword=lung cancer cell line END start-ver=1.4 cd-journal=joma no-vol=45 cd-vols= no-issue=3 article-no= start-page=195 end-page=199 dt-received= dt-revised= dt-accepted= dt-pub-year=1991 dt-pub=199106 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Tissue concentration of doxorubicin (adriamycin) in mouse pretreated with alpha-tocopherol or coenzyme Q10. en-subtitle= kn-subtitle= en-abstract= kn-abstract=<P>The tissue concentration of doxorubicin (adriamycin; ADM) and its major metabolite (aglycone I) was examined in mice pretreated with alpha-tocopherol (VE) or coenzyme Q10 (CoQ). In VE-pretreated group, the concentrations of aglycone I of the liver (1, 3 and 5 h after the administration), kidney (1 and 3h) and heart (3h) were significantly higher than those in the saline group. The clinical application of VE or CoQ concomitant with anti-tumor drugs especially ADM, requires caution.
en-copyright= kn-copyright= en-aut-name=ShinozawaShinya en-aut-sei=Shinozawa en-aut-mei=Shinya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=GomitaYutakata en-aut-sei=Gomita en-aut-mei=Yutakata kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=ArakiYasunori en-aut-sei=Araki en-aut-mei=Yasunori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University en-keyword=doxorubicin kn-keyword=doxorubicin en-keyword=tissue concentration kn-keyword=tissue concentration en-keyword= ?-tocopherol kn-keyword= ?-tocopherol en-keyword=coenzymeQ10 kn-keyword=coenzymeQ10 END start-ver=1.4 cd-journal=joma no-vol=40 cd-vols= no-issue=2 article-no= start-page=65 end-page=73 dt-received= dt-revised= dt-accepted= dt-pub-year=1986 dt-pub=198604 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Establishment and characterization of an adriamycin-resistant subline of human small cell lung cancer cells. en-subtitle= kn-subtitle= en-abstract= kn-abstract=An adriamycin (ADM)-resistant subline was established by continuous exposure of the SBC-3 cells, a cell line of human small cell lung cancer, to increasing concentrations of ADM, followed by the cloning procedure. The resistant sublines (SBC-3/ADM) thus established were 30-fold more resistant to ADM than the parent SBC-3 cells, in terms of the 70% lethal dose determined by soft agar clonogenic assay. The doubling times of the SBC-3 and SBC-3/ADM cells were 36 h and 22 h, respectively. When transplanted into athymic nude mice, the parent as well as resistant cells formed tumors, and serial passage was successful. Although the transplanted tumors from the two cell lines were very similar in histology, the resistance of the SBC-3/ADM cells to ADM developed in vitro was maintained in serially transplanted tumors. The uptake studies with [3H]daunomycin revealed decreased influx and enhanced active efflux of the drug in the resistant cells, whereas cytogenetic analysis showed that the cell lines had an identical karyotype. These results indicate that ADM resistance may be attributed to alternations in membrane transport, resulting in reduced intracellular accumulation of the drug.
en-copyright= kn-copyright= en-aut-name=MiyamotoHiroaki en-aut-sei=Miyamoto en-aut-mei=Hiroaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=Okayama University en-keyword=human small cell lung cancer kn-keyword=human small cell lung cancer en-keyword=adriamycin-resistant subline kn-keyword=adriamycin-resistant subline en-keyword=morphological characteristics kn-keyword=morphological characteristics en-keyword=uptake studies kn-keyword=uptake studies en-keyword=chromosome analysis kn-keyword=chromosome analysis END start-ver=1.4 cd-journal=joma no-vol=40 cd-vols= no-issue=2 article-no= start-page=75 end-page=81 dt-received= dt-revised= dt-accepted= dt-pub-year=1986 dt-pub=198604 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=In vitro chemosensitivity and radiosensitivity of an adriamycin-resistant subline of human small cell lung cancer cells. en-subtitle= kn-subtitle= en-abstract= kn-abstract=Using a cell line (SBC-3/ADM) of human small cell lung cancer, which is 30-fold more resistant to adriamycin than the parent cell line (SBC-3), the activity of a variety of anticancer agents was analyzed by soft agar clonogenic assay to search for a means of circumventing drug resistance. The SBC-3/ADM cells were markedly resistant to some anthracycline antibiotics in comparison with the SBC-3 cells: 28-fold for daunomycin, 26-fold for 4'-epiadriamycin, 18-fold for THP-adriamycin, and 8.4-fold for aclarubicin. However, the cells were as sensitive to mitoxantrone, one of the anthraquinone derivatives, as the parent cells. The cells were resistant to structurally or pharmacodynamically unrelated compounds such as vincristine, mitomycin C, and an active form of ifosfamide, whereas they were susceptible to cisplatin to some extent. The in vitro radiosensitivity of both cell lines was also evaluated, and they were found to be equally sensitive to X-ray. These results suggest that mitoxantrone and cisplatin may exert sufficient activity for small cell lung cancer which has acquired resistance to adriamycin, and that consolidative chest irradiation may be clinically useful after combination chemotherapy including adriamycin.
en-copyright= kn-copyright= en-aut-name=MiyamotoHiroaki en-aut-sei=Miyamoto en-aut-mei=Hiroaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=Okayama University en-keyword=human small cell lung cancer cells kn-keyword=human small cell lung cancer cells en-keyword=adriamycin-resistant subline kn-keyword=adriamycin-resistant subline en-keyword=in vitro chemosensitivity kn-keyword=in vitro chemosensitivity en-keyword=in vitro radiosensitivity kn-keyword=in vitro radiosensitivity END start-ver=1.4 cd-journal=joma no-vol=41 cd-vols= no-issue=1 article-no= start-page=11 end-page=17 dt-received= dt-revised= dt-accepted= dt-pub-year=1987 dt-pub=198702 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Protection against adriamycin (doxorubicin)-induced toxicity in mice by several clinically used drugs. en-subtitle= kn-subtitle= en-abstract= kn-abstract=Protective effects of clinically used drugs against adriamycin (ADM)-induced toxicity were studied in ICR mice. The control mice, which were administered 15 mg/kg of ADM twice, survived 7.48 +/- 1.99 days (mean +/- S.D.). The survival times of mice treated with the following drugs, expressed as a percent of that of the control group, were 293.6% for coenzyme Q10 (Co Q10, 2 mg/kg), 402.2% for dextran sulfate (MDS, 300 mg/kg), 121.6% for flavin adenine dinucleotide (20 mg/kg), 236.3% for adenosine triphosphate disodium (50 mg/kg), 213.7% for reduced glutathione (100 mg/kg), 121.6% for phytonadione (50 mg/kg), 155.2% for inositol nicotinate (Ino-N, 500 mg/kg), 335.5% for nicomol (1000 mg/kg), 157.5% for nicardipine (10 mg/kg) and 123.3% for dipyridamol (50 mg/kg). Anti-hyperlipemic agents such as MDS, nicomol, Ino-N and Co Q10 strongly protected against the ADM-induced toxicity, and the mice administered these drugs lived significantly longer than the control mice. The mechanism of the protective effect was discussed.
en-copyright= kn-copyright= en-aut-name=ShinozawaShinya en-aut-sei=Shinozawa en-aut-mei=Shinya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=GomitaYutaka en-aut-sei=Gomita en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=ArakiYasunori en-aut-sei=Araki en-aut-mei=Yasunori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University en-keyword=adriamycin-toxicity kn-keyword=adriamycin-toxicity en-keyword=survival time kn-keyword=survival time en-keyword=protective effect kn-keyword=protective effect en-keyword=coenzyme Q10 kn-keyword=coenzyme Q10 en-keyword=dextran sulfate kn-keyword=dextran sulfate en-keyword=nicomol kn-keyword=nicomol en-keyword=inositol nicotinate kn-keyword=inositol nicotinate END start-ver=1.4 cd-journal=joma no-vol=47 cd-vols= no-issue=3 article-no= start-page=191 end-page=197 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=199306 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Establishment of an Adriamycin-Resistant Subline of Human Small Cell Lung Cancer Showing Multifactorial Mechanisms of Resistance en-subtitle= kn-subtitle= en-abstract= kn-abstract=A subline highly resistant to Adriamycin (SBC-3/ADM100) was isolated in vitro from the human small cell lung cancer cell line, SBC-3, by culturing in progressively higher concentrations of Adriamycin. The SBC-3/ADM100 cells were 106-fold more resistant to the drug than the parent cells in an inhibitory concentration of 50% determined by the MTT assay. The population-doubling time was much longer in SBC-3/ADM100 than in the parent cells. Northern blot hybridization revealed marked overexpression of the MDR1 mRNA in the resistant cells. P-glycoprotein overexpression and a decrease in intracellular accumulation of Adriamycin were demonstrated in SBC-3/ADM100, indicating that outward drug transport was the major mechanism of resistance in this subline. Additionally, a significant elevation of the intracellular glutathione content coupled with the glutathione S-transferase (GST) pi level and a decrease in DNA topoisomerase II (Topo II) activity were noted in this resistant subline. These results indicate that the mechanism of resistance to Adriamycin is multifactorial; involving altered growth characteristics, an enhanced outward transport, enhanced drug detoxification process, and decreased target enzyme activity. The resistant subline will serve as a useful tool in the search for ways to overcome drug resistance. en-copyright= kn-copyright= en-aut-name=KiuraKatsuyuki en-aut-sei=Kiura en-aut-mei=Katsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OhnoshiTaisuke en-aut-sei=Ohnoshi en-aut-mei=Taisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=TabataMasahiro en-aut-sei=Tabata en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=ShibayamaTakuo en-aut-sei=Shibayama en-aut-mei=Takuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KimuraIkuro en-aut-sei=Kimura en-aut-mei=Ikuro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= affil-num=1 en-affil= kn-affil=Second Department of Medicine, Okayama University Medical School affil-num=2 en-affil= kn-affil=Second Department of Medicine, Okayama University Medical School affil-num=3 en-affil= kn-affil=Second Department of Medicine, Okayama University Medical School affil-num=4 en-affil= kn-affil=Second Department of Medicine, Okayama University Medical School affil-num=5 en-affil= kn-affil=Second Department of Medicine, Okayama University Medical School en-keyword=Adriamycin-resistant cell line kn-keyword=Adriamycin-resistant cell line en-keyword=MDR1 mRNA kn-keyword=MDR1 mRNA en-keyword=glutathione kn-keyword=glutathione en-keyword=glutathione S-transferasse π kn-keyword=glutathione S-transferasse π en-keyword=DNA topoisomerase II kn-keyword=DNA topoisomerase II END start-ver=1.4 cd-journal=joma no-vol=47 cd-vols= no-issue=4 article-no= start-page=243 end-page=248 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=199308 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=MDR1 gene expression and treatment outcome in small cell lung cancer: MDR1 gene expression as an independent prognostic factor. en-subtitle= kn-subtitle= en-abstract= kn-abstract=We report a preliminary study to determine whether MDR1 gene expression level in small cell lung cancer (SCLC) tumors is a useful predictor of tumor response to chemotherapy and patient survival in association with myc amplification in the tumor. We analyzed 18 patients with SCLC receiving adriamycin and etoposide combination chemotherapy between August 1989 and November 1991; 16 males and 2 females, median age of 68 years, and 7 with limited disease and 11 with extensive disease. MDR1 mRNA expression level and myc family gene amplification were simultaneously determined by polymerase chain reaction using transbronchial biopsy specimens which were obtained at diagnosis. Patients with tumors expressing low MDR1 mRNA responded more favorably to chemotherapy than those with tumors expressing high MDRI mRNA, however, the difference in tumor response was statistically not significant (84.6% versus 40%). The overall survival was significantly shorter in the latter than in the former (7.2 months versus 11.7 months; p = 0.023). The survival of the 4 patients with tumor showing myc family gene amplification was almost identical to that of patients with tumors showing no amplification of the gene (8.2 months versus 8.8 months; p = 0.73). Multivariate Cox's regression analysis supports the notion that MDR1 may be a useful independent prognostic factor.
en-copyright= kn-copyright= en-aut-name=TabataMasahiro en-aut-sei=Tabata en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OhnoshiTaisuke en-aut-sei=Ohnoshi en-aut-mei=Taisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=UeokaHiroshi en-aut-sei=Ueoka en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=KiuraKatsuyuki en-aut-sei=Kiura en-aut-mei=Katsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KimuraIkuro en-aut-sei=Kimura en-aut-mei=Ikuro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University en-keyword=small cell lung cancer kn-keyword=small cell lung cancer en-keyword=MDR1 mRNA expression kn-keyword=MDR1 mRNA expression en-keyword=myc gene amplification kn-keyword=myc gene amplification en-keyword=prognostic factor kn-keyword=prognostic factor END start-ver=1.4 cd-journal=joma no-vol=47 cd-vols= no-issue=4 article-no= start-page=233 end-page=241 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=199308 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens. en-subtitle= kn-subtitle= en-abstract= kn-abstract=Antitumor activities of five platinum analogs, including cisplatin, carboplatin, 254-S, DWA2114R, and NK121, were compared using five human lung cancer cell lines and 19 tumor specimens obtained from lung cancer patients. The antitumor activity was evaluated by determining the ratio of the maximum tolerated dose of each drug to the 70% tumor growth inhibitory concentration in a colony assay. Cisplatin was the most potent agent, followed by 254-S and carboplatin. DWA2114R and NK121 were less potent than cisplatin and 254-S. Cross-resistance to adriamycin was also investigated using an adriamycin-resistant small cell lung cancer subline, SBC -3/ADM30. SBC-3/ADM30 was 1.7- to 4.0-fold more resistant to cisplatin, carboplatin, NK121, and DWA2114R, than was the parent line, SBC-3, and the subline was 2.0-fold more sensitive to 254-S. Using SBC-3, in vitro combination effects of etoposide and cisplatin, carboplatin, or 254-S were evaluated by the median-effect principle. Synergism was noted when cisplatin and etoposide were combined at a fixed molar ratio of 1:1. Combination of carboplatin and etoposide showed an additive effect. The combination of 254-S and etoposide was antagonistic at low concentrations, but was markedly synergistic at higher concentrations. These data suggested the efficacy of 254-S in the treatment of lung cancer.
en-copyright= kn-copyright= en-aut-name=YoneiToshiro en-aut-sei=Yonei en-aut-mei=Toshiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OhnoshiTaisuke en-aut-sei=Ohnoshi en-aut-mei=Taisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=HirakiShunkichi en-aut-sei=Hiraki en-aut-mei=Shunkichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=UeokaHiroshi en-aut-sei=Ueoka en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KiuraKatsuyuki en-aut-sei=Kiura en-aut-mei=Katsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=MoritakaTomonori en-aut-sei=Moritaka en-aut-mei=Tomonori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=ShibayamaTakuo en-aut-sei=Shibayama en-aut-mei=Takuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=TabataMasahiro en-aut-sei=Tabata en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=SegawaYoshihiko en-aut-sei=Segawa en-aut-mei=Yoshihiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=TakigawaNagio en-aut-sei=Takigawa en-aut-mei=Nagio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=KimuraIkuro en-aut-sei=Kimura en-aut-mei=Ikuro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= affil-num=1 en-affil= kn-affil=National Okayama Hospital affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama Red Cross Hospital affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University affil-num=9 en-affil= kn-affil=Okayama University affil-num=10 en-affil= kn-affil=Okayama University affil-num=11 en-affil= kn-affil=Okayama University en-keyword=platinum analogs kn-keyword=platinum analogs en-keyword=antitumor activity kn-keyword=antitumor activity en-keyword=lung cancer kn-keyword=lung cancer en-keyword=colony assay kn-keyword=colony assay en-keyword=combination effect kn-keyword=combination effect END start-ver=1.4 cd-journal=joma no-vol=47 cd-vols= no-issue=4 article-no= start-page=289 end-page=292 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=199308 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Disappearance of pulmonary metastases by OK-432 treatment in a case of hepatocellular carcinoma. en-subtitle= kn-subtitle= en-abstract= kn-abstract=We report here a case of hepatocellular carcinoma (HCC) with multiple lung metastases, which were disappeared by treatment of OK-432. The patient was a 65-year-old man and was diagnosed in 1986 with a small (17 x 11 mm) HCC in the anterior-superior segment of the liver. A part of the right hepatic lobe including the tumor was surgically removed, and transarterial injections of adriamycin (10 mg/week) and subcutaneous injections of OK-432 (10 KE/week) were given. Two and a half years later, recurrence of HCC in the liver and its invasion to vena cava inferior (IVC) were found. OK-432 administration was then stopped and percutaneous ethanol injection therapy (PEIT) was performed 10 times. Six months later, the PEIT was effective and the liver tumor with IVC invasion diminished. However, multiple lung metastases were visible on roentgenograms of the chest, and serum alphafetoprotein (AFP) concentration increased to 50,000 ng/ml. The OK-432 treatment resumed. After 6 months of OK-432 treatment, the multiple lung metastases were disappeared and the serum AFP level decreased to 100 ng/ml. At present, the patient is surviving without any sign of recurrence in either the liver or the lung. The clinical course of this case suggests that OK-432 might have effectively treated lung metastases of HCC, although the exact mechanisms are at present unclear.
en-copyright= kn-copyright= en-aut-name=HinoNaoki en-aut-sei=Hino en-aut-mei=Naoki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=HigashiToshihiro en-aut-sei=Higashi en-aut-mei=Toshihiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=UekiTooru en-aut-sei=Ueki en-aut-mei=Tooru kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=NakatsukasaHarushige en-aut-sei=Nakatsukasa en-aut-mei=Harushige kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=OoguchiSouhei en-aut-sei=Ooguchi en-aut-mei=Souhei kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=AshidaKouzou en-aut-sei=Ashida en-aut-mei=Kouzou kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=FujioKouzou en-aut-sei=Fujio en-aut-mei=Kouzou kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=TakakiAkinobu en-aut-sei=Takaki en-aut-mei=Akinobu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=YoneiTaiji en-aut-sei=Yonei en-aut-mei=Taiji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=HasuiToshimi en-aut-sei=Hasui en-aut-mei=Toshimi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=TsujiHideyuki en-aut-sei=Tsuji en-aut-mei=Hideyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=TsujiTakao en-aut-sei=Tsuji en-aut-mei=Takao kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University affil-num=9 en-affil= kn-affil=Okayama University affil-num=10 en-affil= kn-affil=Okayama University affil-num=11 en-affil= kn-affil=Okayama University affil-num=12 en-affil= kn-affil=Okayama University en-keyword=hepatocellular carcinoma kn-keyword=hepatocellular carcinoma en-keyword=OK-432 kn-keyword=OK-432 en-keyword=pulmonary metastasis kn-keyword=pulmonary metastasis END start-ver=1.4 cd-journal=joma no-vol=39 cd-vols= no-issue=5 article-no= start-page=361 end-page=373 dt-received= dt-revised= dt-accepted= dt-pub-year=1985 dt-pub=198510 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Effect of lymphotoxin-like substance (OH-1) on metastatic tumor proliferation. en-subtitle= kn-subtitle= en-abstract= kn-abstract=The effect of a lymphotoxin-like substance, OH-1, released by human acute lymphatic leukemia BALL-1 cells, on metastatic tumor proliferation was investigated in BDF1 mice with transplanted Lewis lung carcinoma cells. Mitomycin-C, cyclophosphamide and adriamycin were used as control agents. The effect of OH-1 on metastases, as determined by comparison of the numbers of pulmonary nodules and by 3H-thymidine labeling indices, was significant. Also, investigation of the effect of OH-1 on host immunity showed that, while the control preparations had considerable side effects, immunodepression and emaciation were not noted with OH-1. As to direct cytotoxicity, OH-1 is principally cytostatic in activity and effects cell progression delay in both the G1 and G2 phases.
en-copyright= kn-copyright= en-aut-name=YamashitaYutaka en-aut-sei=Yamashita en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OritaKunzo en-aut-sei=Orita en-aut-mei=Kunzo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KurimotoMasashi en-aut-sei=Kurimoto en-aut-mei=Masashi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Hayashibara Biochemical Laboratatry en-keyword=lung metastasis kn-keyword=lung metastasis en-keyword=cell cycle kn-keyword=cell cycle en-keyword=autoradiography kn-keyword=autoradiography en-keyword=lymphotoxin kn-keyword=lymphotoxin en-keyword=NK activity kn-keyword=NK activity END start-ver=1.4 cd-journal=joma no-vol=35 cd-vols= no-issue=6 article-no= start-page=395 end-page=405 dt-received= dt-revised= dt-accepted= dt-pub-year=1981 dt-pub=198112 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Tissue distribution and antitumor effect of liposome-entrapped doxorubicin (adriamycin) in Ehrlich solid tumor-bearing mouse. en-subtitle= kn-subtitle= en-abstract= kn-abstract=The usefulness of liposomes (in neutral, positively and negatively charged forms) as a carrier for adriamycin (ADM) was studied by examining the distribution of ADM and related fluorescent compounds in Ehrlich solid tumor-bearing mice. The mice were given free or liposome-entrapped ADM intraperitoneally. The distribution of ADM and related fluorescent compounds between the administration of the free form and liposome-entrapped form was measured by high performance liquid chromatography : The distribution was dependent on the form of the liposomes. The amounts of ADM and its metabolites in the mouse serum 20 min after administration of neutral-liposome-entrapped ADM were 10 times those after the administration of free ADM, 6 times those after the administration of a negatively charged form, and 3.5 times those in the administration of positively charged form. There was no marked difference in the concentrations of these compounds 5 h after administration. The concentration of these compounds in the liver 60 min after administration of each liposome-entrapped form of ADM were in inverse correlation with the concentrations in the serum obtained at 20 min after administration. Total concentrations of ADM and its metabolites in the tumors 20 min after administration of each entrapped form of ADM were 4-5 times that in administration of free ADM after 20 min. There were no marked differences in the concentration of ADM for administration of the various liposome forms. Statistically significant decreases in mean tumor weight were seen in the groups given neutral, positively and negatively charged liposome-entrapped forms compared to corresponding control groups given with free ADM.
en-copyright= kn-copyright= en-aut-name=ShinozawaShinya en-aut-sei=Shinozawa en-aut-mei=Shinya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=ArakiYasunori en-aut-sei=Araki en-aut-mei=Yasunori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=OdaTakuzo en-aut-sei=Oda en-aut-mei=Takuzo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University en-keyword=adriamycin kn-keyword=adriamycin en-keyword=charged liposomes kn-keyword=charged liposomes en-keyword=tissue distribution kn-keyword=tissue distribution en-keyword=antitumor effect kn-keyword=antitumor effect en-keyword= high-performance liquid chromatography (HPLC). kn-keyword= high-performance liquid chromatography (HPLC). END start-ver=1.4 cd-journal=joma no-vol=42 cd-vols= no-issue=5 article-no= start-page=253 end-page=258 dt-received= dt-revised= dt-accepted= dt-pub-year=1988 dt-pub=198810 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Effect of high dose alpha-tocopherol acetate on the toxicity and tissue distribution of adriamycin (doxorubicin). en-subtitle= kn-subtitle= en-abstract= kn-abstract=The effect of alpha-tocopherol acetate (VE) on the toxicity and tissue distribution of adriamycin (ADM) in mice was studied. After the administration of ADM in 2 doses of 15 mg/kg, mice pretreated with olive oil survived 7.1 +/- 1.0 days, while mice pretreated with VE in ten doses of 500 mg/kg/day (subcutaneously) survived 5.5 +/- 1.7 days (p less than 0.01). The total concentration of ADM and its major metabolite, aglycone I in the liver (1, 3, 5 h), kidneys (1, 3 h), and heart (3 h), as determined by high performance liquid chromatography was significantly higher in the VE-pretreated group (four doses of 500 mg/kg/day) than in the olive oil-pretreated group. The aglycone levels of the VE-pretreated group were significantly higher than those of the olive oil-pretreated group in the liver, kidney and heart, but there was no significant difference between the groups in the levels of the unmetabolized form. Considering these results, the administration of VE concomitant with anti-tumor drugs, including ADM, requires great caution.
en-copyright= kn-copyright= en-aut-name=ShinozawaShinya en-aut-sei=Shinozawa en-aut-mei=Shinya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=GomitaYutaka en-aut-sei=Gomita en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=ArakiYasunori en-aut-sei=Araki en-aut-mei=Yasunori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University en-keyword=adriamycin kn-keyword=adriamycin en-keyword=doxorubicin kn-keyword=doxorubicin en-keyword=toxicity kn-keyword=toxicity en-keyword= ?-tocopherol acetate kn-keyword= ?-tocopherol acetate en-keyword=aglycone kn-keyword=aglycone en-keyword=tissue concentrarion kn-keyword=tissue concentrarion END start-ver=1.4 cd-journal=joma no-vol=51 cd-vols= no-issue=3 article-no= start-page=121 end-page=127 dt-received= dt-revised= dt-accepted= dt-pub-year=1997 dt-pub=199706 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Growth inhibitory effects of antifolates against an adriamycin-resistant human small cell lung cancer cell line en-subtitle= kn-subtitle= en-abstract= kn-abstract=We have established an Adriamycin (ADM) -resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM100, which shows multifactorial mechanisms of resistance to ADM, such as overexpression of P-glycoprotein, an enhanced detoxifying system and a decrease in topoisomerase II activity. In the present study, we confirmed that SBC-3/ADM 100 showed collateral sensitivity to methotrexate and TNP-351, a new antifolate, though this cell line showed a typical multidrug resistance (MDR) pattern. We also demonstrated a faster uptake and higher accumulation (1.3-fold) of TNP-351 in the SBC-3/ADM100 cells than those in the parent SBC-3 cells. These results explain one of the mechanisms for collateral sensitivity in the resistant cells. Furthermore, this cell line was found to have no cross-resistance to edatrexate and minimal cross-resistance to trimetrexate, 254-S (cisplatin analog), 5-fluorouracil and 4-hydroperoxyifosfamide. These drugs will have clinical importance in patients with SCLC who were previously treated with an ADM-containing regimen. Thus, antifolates, especially TNP-351 and edatrexate, can be expected to eradicate residual multidrug resistant SCLC cells selected by ADM.
en-copyright= kn-copyright= en-aut-name=MatsuoKeisuke en-aut-sei=Matsuo en-aut-mei=Keisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=KiuraKatsuyuki en-aut-sei=Kiura en-aut-mei=Katsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=UeokaHiroshi en-aut-sei=Ueoka en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=TabataMasahiro en-aut-sei=Tabata en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=ShibayamaTakuo en-aut-sei=Shibayama en-aut-mei=Takuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=MatsumuraTadashi en-aut-sei=Matsumura en-aut-mei=Tadashi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=TakigawaNagio en-aut-sei=Takigawa en-aut-mei=Nagio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=HirakiShunkichi en-aut-sei=Hiraki en-aut-mei=Shunkichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=HaradaMine en-aut-sei=Harada en-aut-mei=Mine kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama Red Cross General Hospital affil-num=9 en-affil= kn-affil=Okayama University en-keyword=Adriamycin-resistant cell line kn-keyword=Adriamycin-resistant cell line en-keyword=antifolates kn-keyword=antifolates en-keyword=small cell lung cancer kn-keyword=small cell lung cancer END start-ver=1.4 cd-journal=joma no-vol=51 cd-vols= no-issue=2 article-no= start-page=93 end-page=99 dt-received= dt-revised= dt-accepted= dt-pub-year=1997 dt-pub=199704 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Preoperative multidisciplinary treatment with hyperthermia for soft tissue sarcoma en-subtitle= kn-subtitle= en-abstract= kn-abstract=We report the results of phase I/II studies of preoperative multidisciplinary treatment of 14 patients with soft tissue sarcoma using hyperthermia from November 1990 to April 1995. The preoperative treatment was conducted with thermo-radio-chemotherapy in 11 cases of stage III, and with thermo-radiotherapy as well as thermo-chemotherapy in three cases of stages I and II. Hyperthermia was carried out twice a week with totals ranging from 4 to 14 times (average: 8.4 times); each session lasted 60min. Radiotherapy was administered four or five times per week, and the dose was 1.8 2Gy/fraction, with a total of 30-40Gy in a four week period. Chemotherapy was mainly in the form of MAID regimen (2-mercaptoethanesulphonic acid (mesna), adriamycin, ifosfamide and dacarbazine). The tumors were surgically resected in all patients after completing the preoperative treatment. The efficacy rate, as expressed by the percentage of either tumors in which reduction rate was 50% or more, or tumors for which post-treatment contrast enhanced CT image revealed low density volumes occupying 50% or more of the total mass, was 71 % (ten of the 14 tumors). The mean tumor necrosis rate in the resected specimens was 78%. The tumor necrosis rate was significantly high (P < 0.05) in patients whose Time ≥ 42°C was of long duration. Postoperative complications were observed in six patients; among these, two patients developed wound infection that required surgical treatment as a complication of surgery performed in the early stage following the preoperative treatment. After a mean postoperative follow-up of 27 months, distant metastasis occurred in four patients resulting in three fatalities. The three-year cumulative survival rate was 64.3%. No local recurrence was observed in any patient during the follow-up, thus confirming our hypothesis that preoperative multidisciplinary treatment has an excellent local efficacy. We think that it would be valuable to conduct, at many facilities, phase III studies on the treatment of soft tissue sarcoma by a combination of surgery and preoperative multidisciplinary treatment using hyperthermia, paying close attention to the interval between these two modalities.
en-copyright= kn-copyright= en-aut-name=MakihataEiichi en-aut-sei=Makihata en-aut-mei=Eiichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KawaiAkira en-aut-sei=Kawai en-aut-mei=Akira kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=OzakiToshifumi en-aut-sei=Ozaki en-aut-mei=Toshifumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=SugiharaShinsuke en-aut-sei=Sugihara en-aut-mei=Shinsuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=InoueHajime en-aut-sei=Inoue en-aut-mei=Hajime kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=JojaIkuo en-aut-sei=Joja en-aut-mei=Ikuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=AsaumiJunichi en-aut-sei=Asaumi en-aut-mei=Junichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University affil-num=9 en-affil= kn-affil=Okayama University affil-num=10 en-affil= kn-affil=Okayama University en-keyword=soft tissue tumor kn-keyword=soft tissue tumor en-keyword=hyperthermia kn-keyword=hyperthermia en-keyword=radiotherapy kn-keyword=radiotherapy en-keyword=chemotherapy kn-keyword=chemotherapy END start-ver=1.4 cd-journal=joma no-vol=36 cd-vols= no-issue=1 article-no= start-page=67 end-page=72 dt-received= dt-revised= dt-accepted= dt-pub-year=1982 dt-pub=198202 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Combination chemotherapy of advanced non-Hodgkin's lymphoma with adriamycin, vincristine, ifosfamide and prednisolone (AVIP): a preliminary report en-subtitle= kn-subtitle= en-abstract= kn-abstract=Eighteen patients with advanced non-Hodgkin's lymphoma other than the diffuse histiocytic type were treated with a combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP). The objective response rate was 83% (15/18); 61% (11/18) achieved complete remission. The median duration of complete remission was 11 months ranging from 2 to 39+ months. Eleven of the 18 patients are still alive during the median follow-up time of 13 months. The median survival was 14+ months for complete responders, and 9.5 months for partial and nonresponders. A myelosuppressive toxicity was well tolerated. AVIP offers some hope as treatment of advanced non-Hodgkin's lymphoma.
en-copyright= kn-copyright= en-aut-name=OhnoshiTaisuke en-aut-sei=Ohnoshi en-aut-mei=Taisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OkaAkira en-aut-sei=Oka en-aut-mei=Akira kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=HayashiKyoichi en-aut-sei=Hayashi en-aut-mei=Kyoichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=UeokaHiroshi en-aut-sei=Ueoka en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=SatoMasaharu en-aut-sei=Sato en-aut-mei=Masaharu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=NishiharaRyuji en-aut-sei=Nishihara en-aut-mei=Ryuji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=YasuokaMasatoshi en-aut-sei=Yasuoka en-aut-mei=Masatoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=SandoYasuhiro en-aut-sei=Sando en-aut-mei=Yasuhiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=TanakaToshio en-aut-sei=Tanaka en-aut-mei=Toshio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=KimuraIkuro en-aut-sei=Kimura en-aut-mei=Ikuro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University affil-num=9 en-affil= kn-affil=Okayama University affil-num=10 en-affil= kn-affil=Okayama University en-keyword=non-Hodgkin's lymphoma kn-keyword=non-Hodgkin's lymphoma en-keyword=combination chemotherapy kn-keyword=combination chemotherapy END start-ver=1.4 cd-journal=joma no-vol=36 cd-vols= no-issue=1 article-no= start-page=61 end-page=66 dt-received= dt-revised= dt-accepted= dt-pub-year=1982 dt-pub=198202 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Effects of steroid sex hormones and adriamycin on human bladder cancer cells in culture. en-subtitle= kn-subtitle= en-abstract= kn-abstract=The effects of steroid sex hormones on the established cell lines derived from human urinary bladder cancer, T24, and from human transitional cell cancer of the urinary tract, 253J, were examined using the colony formation method. Of the seven kinds of steroid hormones tested, estradiol-17 beta was intensively cytotoxic for both cells. The cytotoxic effect was depended on the dose and time of treatment. The combined effect of Adriamycin and estradiol-17 beta on T24 cells could be recognized at low concentrations of Adriamycin (less than or equal to 10(-3) micrograms/ml) after exposure for 24 h.
en-copyright= kn-copyright= en-aut-name=YoshimotoJun en-aut-sei=Yoshimoto en-aut-mei=Jun kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=MatsumuraYosuke en-aut-sei=Matsumura en-aut-mei=Yosuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=TanahashiToyoko en-aut-sei=Tanahashi en-aut-mei=Toyoko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=OhmoriHiroyuki en-aut-sei=Ohmori en-aut-mei=Hiroyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=TokiwaTakayoshi en-aut-sei=Tokiwa en-aut-mei=Takayoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=SatoJiro en-aut-sei=Sato en-aut-mei=Jiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University en-keyword=steroid sex hormones kn-keyword=steroid sex hormones en-keyword=human urinary bladder cancer cell line kn-keyword=human urinary bladder cancer cell line en-keyword=cytotoxic effect kn-keyword=cytotoxic effect en-keyword=adriamycin kn-keyword=adriamycin END start-ver=1.4 cd-journal=joma no-vol=36 cd-vols= no-issue=2 article-no= start-page=125 end-page=132 dt-received= dt-revised= dt-accepted= dt-pub-year=1982 dt-pub=198204 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Pharmacokinetic analysis of adriamycin (doxorubicin) and related fluorescent compounds in Ehrlich tumor-bearing mouse plasma and tissues. en-subtitle= kn-subtitle= en-abstract= kn-abstract=Pharmacokinetic analysis of the distribution and concentration of adriamycin (ADM) in mouse plasma and tissues was carried out by differentiating the unmetabolized form from metabolized ones using high-performance liquid chromatography after a single intravenous injection. Marked differences between ADM and total ADM equivalent values (total ADM values) or its metabolized forms were observed in the pharmacokinetic behavior in plasma and tissue distributions. The ratios of tissue per plasma for total ADM and for ADM values in the liver, kidney and heart showed a two-digit magnitude each time they were examined. Twenty four h later, the ratios for ADM values in the liver, kidney, heart and lung were at high levels; 43.1, 48.1, 57.9 and 45.5 times, respectively. Twenty min after injection the ratios for total ADM values in the spleen, lung and tumors were comparatively small, but 24 h later, the ratio had increased 36.5, 45.5 and 6.8 times respectively.
en-copyright= kn-copyright= en-aut-name=ShinozawaShinya en-aut-sei=Shinozawa en-aut-mei=Shinya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=FukudaTamotsu en-aut-sei=Fukuda en-aut-mei=Tamotsu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=ArakiYasunori en-aut-sei=Araki en-aut-mei=Yasunori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=OdaTakuzo en-aut-sei=Oda en-aut-mei=Takuzo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University en-keyword=adriamycin kn-keyword=adriamycin en-keyword=doxorubicin kn-keyword=doxorubicin en-keyword=pharmacokinetic analysis kn-keyword=pharmacokinetic analysis en-keyword=high-performance liquid chromatography kn-keyword=high-performance liquid chromatography en-keyword=Ehrlich tumor kn-keyword=Ehrlich tumor END start-ver=1.4 cd-journal=joma no-vol=44 cd-vols= no-issue=6 article-no= start-page=321 end-page=323 dt-received= dt-revised= dt-accepted= dt-pub-year=1990 dt-pub=199012 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Successful Chemotherapy on a Pregnant Non-Hodgkin's Lymphoma Patient en-subtitle= kn-subtitle= en-abstract= kn-abstract=We report a case of a non-Hodgkin's lymphoma (NHL) patient treated successfully with combination chemotherapy during pregnancy who delivered a full-term baby. A 29 year-old patient with cervical and inguinal lymphadenopathy in the 27th week of gestation was referred to our hospital. The diagnosis of lymph node biopsy was NHL (diffuse, large cell type with B-cell phenotype). Three courses of CHOP regimen (adriamycin, cyclophosphamide, vincristine and prednisolone) were given before delivery. The patient has been in complete remission for three years and her baby has been in normal development. Our case supports previous reports that chemotherapy in the third trimester may be given safely on NHL patients.
en-copyright= kn-copyright= en-aut-name=TokiHironobu en-aut-sei=Toki en-aut-mei=Hironobu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OkabeHenichi en-aut-sei=Okabe en-aut-mei=Henichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KameiHaruto en-aut-sei=Kamei en-aut-mei=Haruto kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=ShimokawaTatsuo en-aut-sei=Shimokawa en-aut-mei=Tatsuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=HiuraMasamichi en-aut-sei=Hiura en-aut-mei=Masamichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=KondoMasashi en-aut-sei=Kondo en-aut-mei=Masashi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=HirotaYuichi en-aut-sei=Hirota en-aut-mei=Yuichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= affil-num=1 en-affil= kn-affil=Shikoku Cancer Center Hospital affil-num=2 en-affil= kn-affil=Shikoku Cancer Center Hospital affil-num=3 en-affil= kn-affil=Shikoku Cancer Center Hospital affil-num=4 en-affil= kn-affil=Shikoku Cancer cernter Hospital affil-num=5 en-affil= kn-affil=Shikoku Cancer Center Hospital affil-num=6 en-affil= kn-affil=Matsuyama Red Cross Hospital affil-num=7 en-affil= kn-affil=Matsuyama Red Cross Hospital en-keyword=non-Hodgkin's lymphoma kn-keyword=non-Hodgkin's lymphoma en-keyword=pregnancy kn-keyword=pregnancy en-keyword=chemotherapy kn-keyword=chemotherapy END start-ver=1.4 cd-journal=joma no-vol=38 cd-vols= no-issue=1 article-no= start-page=57 end-page=63 dt-received= dt-revised= dt-accepted= dt-pub-year=1984 dt-pub=198402 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Effect of coenzyme Q10 on the survival time and lipid peroxidation of adriamycin (doxorubicin) treated mice. en-subtitle= kn-subtitle= en-abstract= kn-abstract=The effect of coenzyme Q10 (Co Q10) was examined on the survival time and lipid peroxidation of adriamycin (ADM)-treated ICR mice. Co Q10 showed a protective effect against a subacute toxicity in mice induced by two intraperitoneal administrations of ADM (15 mg/kg). The group treated orally with 10 mg/kg of Co Q10 showed the longest survival time of all the groups studied (16.81 +/- 10.29 days, mean +/- S.D.) and a significantly longer survival time (p less than 0.001) than the ADM-alone group (7.48 +/- 1.99 days). The inhibitory effect of Co Q10 on the plasma and tissue lipid peroxidation levels did not correlate with the effect of prolonging the survival time of mice. Co Q10 tended to inhibit rises in plasma and liver lipid peroxidation levels induced by ADM administration, but there was no statistically significant difference between treatments. There was a statistically significant different inhibitory effect in the kidney lipid peroxidation levels, but was not in those of the heart.
en-copyright= kn-copyright= en-aut-name=ShinozawaShinya en-aut-sei=Shinozawa en-aut-mei=Shinya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=EtowoKouhei en-aut-sei=Etowo en-aut-mei=Kouhei kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=ArakiYasunori en-aut-sei=Araki en-aut-mei=Yasunori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=OdaTakuzo en-aut-sei=Oda en-aut-mei=Takuzo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University en-keyword=coenzymeQ10 kn-keyword=coenzymeQ10 en-keyword=adriamycin kn-keyword=adriamycin en-keyword=doxorubicin kn-keyword=doxorubicin en-keyword=lipid peroxidation kn-keyword=lipid peroxidation en-keyword=plasma and tissues kn-keyword=plasma and tissues en-keyword=toxicity kn-keyword=toxicity END start-ver=1.4 cd-journal=joma no-vol=38 cd-vols= no-issue=6 article-no= start-page=501 end-page=504 dt-received= dt-revised= dt-accepted= dt-pub-year=1984 dt-pub=198412 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Interaction between human lymphoblastoid interferon and chemotherapeutic agents in vitro. en-subtitle= kn-subtitle= en-abstract= kn-abstract=The combined effect of human lymphoblastoid interferon (HLBI) and anticancer agents on the growth of MOLT-4 was studied in vitro. The interferon showed a strikingly synergistic interaction in combination with aclarubicin, cytosine arabinoside or prednisolone. It was moderately synergistic in combination with adriamycin or 5-fluorouracil and tended to show additive effects with daunorubicin or vincristine. In vitro studies of combination chemotherapy with interferon and anticancer agents should yield valuable information as to the best combination for man.
en-copyright= kn-copyright= en-aut-name=TakahashiIsao en-aut-sei=Takahashi en-aut-mei=Isao kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OdaYasuhiro en-aut-sei=Oda en-aut-mei=Yasuhiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=LaiMinyu en-aut-sei=Lai en-aut-mei=Minyu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=FukumotoMitsuhiro en-aut-sei=Fukumoto en-aut-mei=Mitsuhiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=NishimuraMasataka en-aut-sei=Nishimura en-aut-mei=Masataka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=YorimitsuSeiichi en-aut-sei=Yorimitsu en-aut-mei=Seiichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=KitajimaKoichi en-aut-sei=Kitajima en-aut-mei=Koichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=KimuraIkuro en-aut-sei=Kimura en-aut-mei=Ikuro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University en-keyword=human lymphoblastoid interferon kn-keyword=human lymphoblastoid interferon en-keyword=in vitro chemotherapy kn-keyword=in vitro chemotherapy en-keyword=interaction of anticancer agents kn-keyword=interaction of anticancer agents END start-ver=1.4 cd-journal=joma no-vol=94 cd-vols= no-issue=9-10 article-no= start-page=921 end-page=930 dt-received= dt-revised= dt-accepted= dt-pub-year=1982 dt-pub=198210 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Analysis of DNA replication of SV40 chromatin in digitonin-treated permeable cells kn-title=ジギトニン処理透過性細胞内におけるSV40クロマチンDNA複製の解析 en-subtitle= kn-subtitle= en-abstract=The ultrastructure of digitonin-treated permeable cells and various conditions for DNA replication of SV40 chromatin as well as the requirements for and inhibitors of DNA synthesis were analyzed. Electron microscopy of the permeable cells revealed that the plasma membrane was injured but inner membranes and nuclear chromatin remained relatively intact. Efficient DNA replication of SV40 chromatin in the present system requires the addition of dATP, dCTP, dGTP, dTTP, ATP and Mg(2+). Complete replication of SV40 chromatin DNA occurs without addition of cytosol. The DNA synthesis is almost completely inhibited by ethylenediamin-tetraacetic acid, N-ethylmaleimide, aphidicolin, and arabinosyl-cytidine triphosphate but not by 2', 3'-dideoxythymidine -5'-triphosphate, showing that the DNA synthesis is replicative. Adriamycin strongly inhibits the DNA replication, and the addition of adriamycin in the process of reaction immediately stops the DNA replication. Thus, the digitonin-treated permeable cell system serves as a useful system for studying in vitro replication of chromatin DNA in eukaryotic cells as well as for studying the in vitro action of adriamycin and other antitumor drugs which inhibit DNA replication. kn-abstract=真核細胞におけるクロマチンDNAの複製とその調節機構を研究するために, SV40感染細胞を低濃度のジギトニン処理し,基質透過性とした細胞(permeable cell)の超微構造と同細胞内におけるSV40クロマチンDNA複製系の諸条件を検討し,基質要求性と阻害剤や制癌剤の影響を解析した.その結果, ①至適なジギトニン濃度(100～150μg/ml),処理温度(25℃),塩濃度(50～100μM KCl),蔗糖濃度(0.1～0.15M), Mg(2+)濃度(5～7mM),反応温度(30°～37℃)などの基礎的諸条件を決定した. ②このジギトニン処理透過性細胞は超微構造的に細胞膜は障害されているが,他の内膜系や核クロマチンは比較的よく保たれている. ③この透過性細胞系では,細胞質抽出液を加えなくても,基質としての4種のデオキシリボヌクレオシド三リン酸(d ATP, d CTP, d GTP,各0.1mM, dTTP, 0.01mM)の他, ATP(2～5mM)とMg(2+) (5mM)の添加で効率のよいDNA合成が行なわれる. ④EDTA, NEM,アフィディコリン, ara CTPでDNA合成がほとんど完全に阻害され, dd TTPでは全く阻害されないので,この系のDNA合成は複製的DNA合成である. ⑤アドリアマイシンなどの制癌剤でSV40 DNAの複製が直ちに強く阻害されることを見出した.したがって,本実験系は真核細胞におけるクロマチンDNAのin vitro複製の研究のみならず,アドリアマイシンなどのDNA合成阻害制癌剤の作用を調べる上に極めて有用な実験系として役立つものと考えられる. en-copyright= kn-copyright= en-aut-name=HanakawaShiro en-aut-sei=Hanakawa en-aut-mei=Shiro kn-aut-name=花川志郎 kn-aut-sei=花川 kn-aut-mei=志郎 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部整形外科教室 en-keyword=ジギトニン kn-keyword=ジギトニン en-keyword=透過性細胞 kn-keyword=透過性細胞 en-keyword=SV40 kn-keyword=SV40 en-keyword=クロマチン kn-keyword=クロマチン en-keyword=DNA複製 kn-keyword=DNA複製 END start-ver=1.4 cd-journal=joma no-vol=94 cd-vols= no-issue=7-8 article-no= start-page=673 end-page=681 dt-received= dt-revised= dt-accepted= dt-pub-year=1982 dt-pub=19820830 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on the diagnosis and treatment of human lung cancer using double-layered soft agar cloning assay I. In vitro chemosensitivity test on permanent cell lines from adeno-, epidermoid and small cell carcinoma of the lung using double-layered soft agar cloning assay kn-title=コロニー形成法を利用したヒト肺癌の診断ならびに治療に関する研究 第1編 ヒト肺癌細胞株(腺癌,扁平上皮癌,小細胞癌)のin vitro制癌剤感受性試験 en-subtitle= kn-subtitle= en-abstract= kn-abstract=An in vitro chemosensitivity test on permanent cell lines from adeno-, epidermoid and small cell carcinoma of the lung was performed using a double-layered soft agar cloning assay. Drugs tested in the present study were Adriamycin, 40497S, Mitomycin C, cis-Dichlorodiammineplatinum, Methotrexate and Vincristine. Adriamycin, 40497S, Mitomycin C and cis-Dichlorodiammineplatinum showed dose-dependent cytotoxity. Methotrexate and Vincristine did not show a significant cytotoxity when the cell lines were exposed for one hour. Differences in chemosensitivity to the six drugs examined among the three cell lines was relatively small e.g. the lethal dose 90% (LD90) of Adriamycin was 0.19mcg/ml in adenocarcinoma, 0.46mcg/ml in epidermoid carcinoma and 0.27mcg/ml in small cell carcinoma. The lack of a difference in chemosensitivity in vitro might be attributed to the fact that the cell lines had been established from bronchogenic carcinomas which were refractory to intensive combination chemotherapy. en-copyright= kn-copyright= en-aut-name=MiyaiMasahiro en-aut-sei=Miyai en-aut-mei=Masahiro kn-aut-name=宮井正博 kn-aut-sei=宮井 kn-aut-mei=正博 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第2内科学教室 en-keyword=human lung cancer cell lines kn-keyword=human lung cancer cell lines en-keyword=in vitro chemosensitivity test kn-keyword=in vitro chemosensitivity test en-keyword=cloning assay kn-keyword=cloning assay END start-ver=1.4 cd-journal=joma no-vol=98 cd-vols= no-issue=9-10 article-no= start-page=759 end-page=770 dt-received= dt-revised= dt-accepted= dt-pub-year=1986 dt-pub=19861031 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on chemotherapy for advanced lung cancer Part 1. An alternating non-cross-resistant combination chemothepay (COMP-VAN) for extensive small cell lung cancer kn-title=進展期肺癌の化学療法に関する研究 第1編 肺小細胞癌extensive disease症例における多剤併用交替療法(COMP-VAN) en-subtitle= kn-subtitle= en-abstract= kn-abstract=Fifty-two patients with extensive small lung cancer entered a study of cyclic alternating combination chemotherapy between February 1981 and December 1984. The chemotherapy consisted of a four-drug combination of cyclophosphamide (CPA), vincristine (VCR), methotrexate (MTX) and procarbazine (PCZ), and a three-drug combination of etoposide (VP-16), adriamycin (ADM) and nimustine hydrochloride (ACNU). The doses and schedule were as follows: CPA, 270mg/㎡, i.v., day 1-5; VCR, 1.4mg/㎡, i.v., day 1; MTX, 6.5mg/㎡, i.m., day 1-5; PCZ, 65mg/㎡, p.o., day 1-5; VP-16, 140mg/㎡, p.o., day 29-32; ADM, 40mg/㎡, i.v., day 29; ACNU, 40mg/㎡, i.v., day 29. Cycles were repeated every 8 weeks. Of 52 patients, 45 were fully evaluated for tumor response and toxicity. The overall response rate was 89%, and the complete response rate was 33%. The median survival time of all the patients who could be evaluated was 11.0 months: 16.5 months for complete responders, 10.0 months for partial responders, and 6.5 months for non-responders. Responders lived significantly longer than non-responders. The major toxicity was myelosuppression. However, patients tolerated the chemotherapy well, and no patients encountered life-threatening complications. The cyclic alternating chemotherapy appears beneficial compared to the four-drug combination of CPA, VCR, MTX and PCZ. en-copyright= kn-copyright= en-aut-name=OzawaShiro en-aut-sei=Ozawa en-aut-mei=Shiro kn-aut-name=小澤志朗 kn-aut-sei=小澤 kn-aut-mei=志朗 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=肺癌 kn-keyword=肺癌 en-keyword=小細胞癌 kn-keyword=小細胞癌 en-keyword=多剤併用交替療法 kn-keyword=多剤併用交替療法 en-keyword=COMP-VAN kn-keyword=COMP-VAN END start-ver=1.4 cd-journal=joma no-vol=98 cd-vols= no-issue=7-8 article-no= start-page=645 end-page=655 dt-received= dt-revised= dt-accepted= dt-pub-year=1986 dt-pub=19860830 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on treatment of malignant lymphoma Part 1. Combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP) for malignant lymphomas refractory to conventional chemotherapy kn-title=悪性リンパ腫の治療に関する研究 第1編 化学療法不応例および再発例に対するadriamycin, vincristine, ifosfamideおよびprednisolone併用(AVIP)療法 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Fifty-seven patients with advanced malignant lymphoma, who had failed to achieve complete remission or relapsed after conventional combination chemotherapy, were treated with a combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP). Twenty-five patients were given relatively low doses of adriamycin (0.5mg/kg), vincristine (0.025mg/kg), and ifosfamide (25mg/kg) at 7-day intervals (Regimen I), and the remaining 32 patients were given relatively high doses of these drugs (1.2mg/kg of adriamycin, 50mg/kg of ifosfamide and 0.03mg/kg of vincristine) at 21-day intervals (Regimen Ⅱ). Among 8 patients with Hodgkin's disease, 7 (88%) achieved objective remission including 4 (50%) complete remissions, and 3 complete respondors remain disease free in a follow-up from 44 months to 89 months. The overall median survival was more than 50 months, ranging from 12 months to more than 90 months. Among 49 patients with non-Hodgkin's lymphoma, 32 (65%) achieved objective remission including 15 (31%) complete remissions. The median duration of complete remission was 8 months, and 3 complete respondors remain disease free at 13, 36 and 90 months, respectively. The overall median survival was 8 months, ranging from 2 months to more than 91 months. The diffuse large cell type was the most frequent in non-Hodgkin's lymphoma. Among 27 patients with this histologic type, 17(63%) had objective remission including 7 (26%) complete remissions. The median duration of complete remission and the median survival were 11 months and 8 months, respectively. There were no significant differences in the therapeutic results of Regimen I and Regimen Ⅱ, although the latter showed a slightly higher response rate and longer duration of complete remission in non-Hodgkin's lymphoma. Reversible bone marrow toxicity was the major toxic reaction, but both regimens were well tolerated. These results indicate that a combination of AVIP is useful for treatment of malignant lymphomas refractory to conventional chemotherapy. en-copyright= kn-copyright= en-aut-name=HayashiKyoichi en-aut-sei=Hayashi en-aut-mei=Kyoichi kn-aut-name=林恭一 kn-aut-sei=林 kn-aut-mei=恭一 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学第2内科 en-keyword=悪性リンパ腫 kn-keyword=悪性リンパ腫 en-keyword=多剤併用療法 kn-keyword=多剤併用療法 en-keyword=前治療不応例 kn-keyword=前治療不応例 END start-ver=1.4 cd-journal=joma no-vol=97 cd-vols= no-issue=7-8 article-no= start-page=661 end-page=676 dt-received= dt-revised= dt-accepted= dt-pub-year=1985 dt-pub=19850830 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on combination chemotherapy for malignant lymphomaPart II. Combination chemotherapy in malignant lymphoma: Results of a long-term follow-up kn-title=悪性リンパ腫の化学療法に関する研究 第2編 進展期悪性リンパ腫に対する多剤併用療法の治療効果:長期観察による検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Results of combination chemotherapy for malignant lymphoma between 1973 and 1982 were analysed. In this series there were 17 patients with Hodgkin's disease (HD) and 109 patients with non-Hodgkin's lymphoma (NHL). None of the patients had prior chemotherapy. The two basic treatment programs in this series were BVCP or BCOP (combination of bleomycin, vincristine, cyclophosphafamide and prednisolone) and AVIP(combination of adriamycin, vincristine, ifosfamide and prednisolone). Of the 17 HD patients, 14 (82%) were effectively treated and achieved complete remission(CR). Six of the 14 patients relapsed between 15 and 65 months, while the remaining 8 patients have been disease-free between 8 and 126 months. The projected median CR duration was 65 months. No recurrent disease has occurred among 5 patients who were given AVIP as intensification therapy, suggesting the usefulness of adriamycin in the treatment of HD. Complete responders survived significantly longer than partial responders: 83% of the former survived 5 years, but none of the latter survived that long. Of the 109 patients with NHL, 25 patients had diffuse medium cell type histology(DM) and 43 patients had diffuse large cell type histology(DL). For DM, the CR rate was 64%, and the median response duration was 10 months. Of the 16 CRs, 9 have relapsed so far; however, the remaining 7 have been disease free for 12 to 95 months. For DL, the CR rate was 63% and the median remission duration was 43 months. Of the 27 CRs, 13 have relapsed so far, but the remaining 14 have been disease free for 13 to 115 months. The median survival time was 75 months for DM, and 23 months for DL. Complete responders lived significantly longer than partial or none-responders in DL. Prognostic factors were analysed in DM and DL patients. Among the chemotherapy effect, stage, constitutional symptoms, serum LDH, C-reactive protein (CRP), lymphocyte count of peripheral blood, and erythrocyte sedimentation rate(ESR), a CRP over 3+ and ESR over 30mm/hr were defined as poor prognostic factors for DM. Remission induction failure and CRP over 3+ were defined as poor prognostic factors for DL. Sixteen (6 HD and 10 NHL) of 72 complete responders (14 HD and 58 NHL) were disease free for at least 2 years after cessation of all treatment, suggesting that HD as well as NHL is curable by intensive combination chemotherapy. en-copyright= kn-copyright= en-aut-name=NishiharaRyuji en-aut-sei=Nishihara en-aut-mei=Ryuji kn-aut-name=西原龍司 kn-aut-sei=西原 kn-aut-mei=龍司 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第2内科学教室 en-keyword=悪性リンパ腫 kn-keyword=悪性リンパ腫 en-keyword=多剤併用療法 kn-keyword=多剤併用療法 en-keyword=予後因子 kn-keyword=予後因子 END start-ver=1.4 cd-journal=joma no-vol=97 cd-vols= no-issue=7-8 article-no= start-page=649 end-page=660 dt-received= dt-revised= dt-accepted= dt-pub-year=1985 dt-pub=19850830 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on combination chemotherapy for malignant lymphomaPart I. Drug screening and combination chemotherapy usinga murine lymphosarcoma, LS-1, as a model of malignant lymphoma in man. kn-title=悪性リンパ腫の化学療法に関する研究 第1編 マウス自然発生リンパ肉腫(LS-1)をモデルとした悪性リンパ腫の化学療法に関する検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=A murine lymphosarcoma (LS-1) which originated spontaneously in a DBA/2 mouse, was evaluated as a model of malignant lymphoma for drug screening and combination chemotherapy. Antitumor activity was distinct in the order of L-asparaginase (LASP), mitoxantrone, a new anthraquinone analogue (MIT), ifosfamide (IFO), cyclophosphamide (CPA), adriamycin (ADM), and aclarubicin, a new ADM analogue (ACR), when measured as increased life span of mice intravenously implanted with LS-1 and intraperitoneously treated with antitumor agents at an optimal dose. Methotrexate (MTX), vincristine (VCR), and vindesine (VDS) were marginally active against LS-1. Nitrosourea compounds, such as BCNU and ACNU, and bleomycin were inactive against the tumor. The murine lymphosarcoma, LS-1, appeared to provide a drug activity spectrum closely analogous to malignant lymphoma in man except for LASP. The combination of IFO and MIT was the most effective among six 2-drug combinations. CPA and MIT, IFO and ADM, and CPA and ADM were also effective combination. ACR, however, appeared antagonistic to IFO and CPA, since in combination with these agents, ACR did not prolong the life-span at any dose, as compared to the optimal dose of IFO or CPA alone. The murine experimental system using LS-1 should be usefull as a chemotherapy model of malignant lymphoma in man. en-copyright= kn-copyright= en-aut-name=NishiharaRyuji en-aut-sei=Nishihara en-aut-mei=Ryuji kn-aut-name=西原龍司 kn-aut-sei=西原 kn-aut-mei=龍司 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第2内科学教室 en-keyword=マウス悪性リンパ腫 kn-keyword=マウス悪性リンパ腫 en-keyword=化学療法 kn-keyword=化学療法 en-keyword=多剤併用療法 kn-keyword=多剤併用療法 END start-ver=1.4 cd-journal=joma no-vol=97 cd-vols= no-issue=3-4 article-no= start-page=263 end-page=276 dt-received= dt-revised= dt-accepted= dt-pub-year=1985 dt-pub=19850430 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Treatment of Advanced Malignant Lymphoma Part 2. Adriamycin-induced Cardiotoxicity kn-title=悪性リンパ腫の治療に関する研究 第2編 Adriamycinの心毒性に関する研究-悪性リンパ腫症例を中心に- en-subtitle= kn-subtitle= en-abstract= kn-abstract=For the assessment of adriamycin (ADM)-induced cardio-toxicity, myocardial scintigraphy using technetium-99m pyrophosphate; electrocardiography, measuring the QRS voltage and QTc; mechanocardiography, measuring the systolic time interval (STI) and echocardiography, measuring the ejection fraction (EF) were performed in patients with malignant disease, mainly in those with malignant lymphoma. In a retrospective study, 17 patients who had received ADM therapy underwent cardiac evaluation after completion of the therapy. Out of these patients, 3 who had been given a total dose of ADM of 493mg/m(2), 545mg/m(2) and 705mg/m(2) developed congestive heart failure. Myocardial scintigrams showed the best correlation with the cumulative dose of ADM and congestive heart failure. Based on the results from the retrospective study, a prospective study was performed in 29 patients. Cardio-toxicity was evaluated at a cumulative ADM dose of 400mg/m(2) and 500mg/m(2) using the same means as in the retrospective study. ADM therapy was discontinued when a cumulative ADM dose of 500mg/m(2) was reached or a positive myocardial scintigram was observed. No patients developed congestive heart failure. Myocardial scintigrams were affected by the age of the patient. Among the QRS voltage, QTc, STI and EF, the QRS voltage correlated best with myocardial scintigrams; however, the QRS voltage seemed to be less sensitive than myocardial scintigrams for the early detection of ADM-induced cardiomyopathy. It is concluded that discontinuation of ADM at the time of a positive myocardial scintigram is a good way to avoid ADM-induced cardiomyopathy. en-copyright= kn-copyright= en-aut-name=UeokaHiroshi en-aut-sei=Ueoka en-aut-mei=Hiroshi kn-aut-name=上岡博 kn-aut-sei=上岡 kn-aut-mei=博 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第2内科 en-keyword=Adriamycin kn-keyword=Adriamycin en-keyword=Cardiotoxicity kn-keyword=Cardiotoxicity en-keyword=Myocardial scintigram kn-keyword=Myocardial scintigram END start-ver=1.4 cd-journal=joma no-vol=97 cd-vols= no-issue=3-4 article-no= start-page=249 end-page=261 dt-received= dt-revised= dt-accepted= dt-pub-year=1985 dt-pub=19850430 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Treatment of Advanced Malignant LymphomaPart 1. Combination Chemotherapy for Advanced Non Hodgkin's Lymphoma with Adriamycin, Vincristine, Ifosfamide, and Prednisolone. kn-title=悪性リンパ腫の治療に関する研究 第1編 非ホジキンリンパ腫におけるAdriamycin, Vincristine, IfosfamideおよびPrednisolone併用療法の検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Twenty-nine patients with advanced non-Hodgkin's lymphoma (3 with follicular medium-sized cell type, 1 with follicular mixed cell type, 5 with diffuse small cell type, 17 with diffuse medium-sized cell type and 3 with lymphoblastic type) were treated with a four-drug combination chemotherapy consisting of adriamycin, vincristine, ifosfamide and prednisolone (AVIP). The objective response rate was 89% with a complete response rate of 55%. The median duration of complete response was 10 months ranging from 2 months to 6 years and 7 months. The median survival time calculated by the Kaplan-Meier method was 3 years and 9 months. As for the 17 patients with diffuse medium-sized cell type lymphoma, the complete response rate was 71%. Median survival time has not been reached, and 62% of the patients were alive after 5 years. Performance status, and presence or absence of systemic symptoms were important factors in predicting survival. The myelosuppressive toxicity of the regimen was well tolerated. No patients encountered life-threatening toxicity. This study demonstrated the efficacy of the AVIP regimen in patients with non-Hodgkin's lymphoma, and it appeared that patients with diffuse medium-sized cell type lymphoma were potentially curable. en-copyright= kn-copyright= en-aut-name=UeokaHiroshi en-aut-sei=Ueoka en-aut-mei=Hiroshi kn-aut-name=上岡博 kn-aut-sei=上岡 kn-aut-mei=博 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第2内科 en-keyword=Non-Hodgkin's lymphoma kn-keyword=Non-Hodgkin's lymphoma en-keyword=Combination chemotherapy kn-keyword=Combination chemotherapy en-keyword=Prognostic factor kn-keyword=Prognostic factor END start-ver=1.4 cd-journal=joma no-vol=99 cd-vols= no-issue=9-10 article-no= start-page=1197 end-page=1204 dt-received= dt-revised= dt-accepted= dt-pub-year=1987 dt-pub=19871031 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on aortic medial smooth muscle cell culture Part 2. The effects of vitamin E on the proliferation of cells derived from aged or diabetic rats kn-title=大動脈中膜平滑筋細胞培養に関する研究 第2編 加齢及び糖尿病ラット由来細胞におけるビタミンEの細胞増生に対する影響 en-subtitle= kn-subtitle= en-abstract= kn-abstract=We found in the segment of this study that lipid peroxides inhibit the proliferation of aortic medial smooth muscle cells derived from rats with streptozotocin-induced diabetes (STZ-rats) and normal cells cultured in an adriamycin-containing medium. It was then supposed that vitamin E, an antioxidant, may restore cell proliferation by its inhibitory effect on lipid peroxides. This led us to study the effect of vitamin E on the proliferation of cells derived from STZ-rats and normal cells cultured in an adriamycin-containing medium. The growth rate of normal cells was increased by the addition of vitamin E. However, its effect was reduced with aging. on the other hand, the growth rate of cells derived from STZ-rats was hardly affected and intracellular synthesis of lipid peroxides was not attenuated by the addition of vitamin E. The effect of vitamin E on cell proliferation and the synthesis of intracellular lipid peroxides was not found in cells obtained 12 months after STZ injection. Adriamycin inhibited normal cell proliferation concentration-dependently with an increase in intracellular lipid peroxides. However, when normal cells were planted in a medium containing adriamycin and vitamin E, the effect of adriamycin on cell proliferation was reduced. Namely, when lipid peroxides coexisted with adriamycin for a short period of time, vitamin E prevented the effect of lipid peroxides on cell proliferation. However, when they remained in the cells for a long period of time, vitamin E did not show any inhibitory effect on the lipid peroxides. The results suggest that the effect of vitamin E on cell proliferation is dependent on the period of intracellular existence of lipid peroxides. en-copyright= kn-copyright= en-aut-name=IshiokaTatsuji en-aut-sei=Ishioka en-aut-mei=Tatsuji kn-aut-name=石岡達司 kn-aut-sei=石岡 kn-aut-mei=達司 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科教室 en-keyword=ビタミンE kn-keyword=ビタミンE en-keyword=大動脈中膜平滑筋培養 kn-keyword=大動脈中膜平滑筋培養 en-keyword=過酸化脂質 kn-keyword=過酸化脂質 en-keyword=糖尿病 kn-keyword=糖尿病 en-keyword=加齢 kn-keyword=加齢 END start-ver=1.4 cd-journal=joma no-vol=99 cd-vols= no-issue=9-10 article-no= start-page=1189 end-page=1196 dt-received= dt-revised= dt-accepted= dt-pub-year=1987 dt-pub=19871031 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on aortic medial smooth muscle cell culture Part 1. The effects of lipid peroxides on cell proliferation in cells derived from aged or diabetic rats kn-title=大動脈中膜平滑筋細胞培養に関する研究 第1編 加齢及び糖尿病ラット由来細胞における過酸化脂質の細胞増生に対する影響について en-subtitle= kn-subtitle= en-abstract= kn-abstract=The cultured smooth muscle cell offers several advantages to investigation of cell character. It can be utilized to make studies on aging and atherosclerosis. This work was carried out to investigate the effects of intracellular lipid peroxides and aging on the growth rate of cultured aortic medial smooth muscle cells obtained from normal rats and rats with streptozotosin-induced rats. Cells from young and old rats showed similar growth and contained the same amount of intracellular lipid peroxides. However the rate of growth of cells from diabetic rats was inversely proportional to the period of illness and also to the quantity of lipid peroxides contained in the cells. When normal cells were cultured in an adriamycin-containing medium, their growth rate was inversely proportional to the adriamycin concentration of the medium and also the amount of intracellular lipid peroxides. en-copyright= kn-copyright= en-aut-name=IshiokaTatsuji en-aut-sei=Ishioka en-aut-mei=Tatsuji kn-aut-name=石岡達司 kn-aut-sei=石岡 kn-aut-mei=達司 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=過酸化脂質 kn-keyword=過酸化脂質 en-keyword=大動脈中膜平滑筋培養 kn-keyword=大動脈中膜平滑筋培養 en-keyword=糖尿病 kn-keyword=糖尿病 en-keyword=加齢 kn-keyword=加齢 END start-ver=1.4 cd-journal=joma no-vol=99 cd-vols= no-issue=9-10 article-no= start-page=1167 end-page=1178 dt-received= dt-revised= dt-accepted= dt-pub-year=1987 dt-pub=19871031 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on multidisciplinary treatment of small cell lung cancer Part I. A randomized trial comparing chemotherapy alone with chemotherapy plus chest irradiation kn-title=肺小細胞癌の集学的治療に関する研究 第1編 肺小細胞癌limited disease症例における胸部照射併用の意義について：無作為化比較試験による検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=In order to assess the effectiveness of chest irradiation in addition to intensive chemotherapy in the treatment of limited stage small cell lung cancer, 56 patients were randomized to receive either chemotherapy alone or chemotherapy plus chest irradiation, between April 1981 and September 1986. The chemotherapy regimen consisted of a four-drug combination of cyclophosphamide, vincristine, methotrexate and procarbazine, and a three-drug combination of VP-16, adriamycin and nimustine, given alternately every 8 weeks. One group of 28 patients received chemotherapy alone, and another group of 28 patients received chest irradiation of 40Gy, in 20 fractions over 4 weeks, between cycles 1 and 2 of the chemotherapy. Complete response rate were similar in the two groups; 46% for those receiving chemotherapy alone, and 62% for those receiving chemotherapy plus chest irradiation. There was no significant difference in the median survival time (14.5 months for chemotherapy alone versus 12.0 months for chemotherapy plus chest irradiation). The combined modality treatment was more toxic than chemotherapy alone; two patients receiving such treatment died of radiation pneumonitis. However, as far as the 3-year survival rate, there was a trend favoring patients receiving the combined modality treatment (11% versus 19%). Although additional studies are required to determine the optimal dose and schedule, timing, and selection of patients as for chest irradiation, the major need for the treatment of small cell lung cancer is better systemic chemotherapy. It seems likely that the role of chest irradiation will become more important as improved chemotherapy is developed. en-copyright= kn-copyright= en-aut-name=KawaharaShin en-aut-sei=Kawahara en-aut-mei=Shin kn-aut-name=河原伸 kn-aut-sei=河原 kn-aut-mei=伸 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第2内科教室 en-keyword=肺小細胞癌 kn-keyword=肺小細胞癌 en-keyword=limited disease kn-keyword=limited disease en-keyword=化学療法 kn-keyword=化学療法 en-keyword=胸部照射 kn-keyword=胸部照射 END start-ver=1.4 cd-journal=joma no-vol=100 cd-vols= no-issue=7-8 article-no= start-page=753 end-page=761 dt-received= dt-revised= dt-accepted= dt-pub-year=1988 dt-pub=1988 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Experimental and clinical studies on the treatment of lung cancer.Part 1: Drug screening and combination chemotherapy using advanced Lewis lung carcinoma as a model of human lung cancer. kn-title=肺癌の治療に関する基礎的並びに臨床的研究 第1編 実験肺癌（Lewis lung carcinoma）をモデルとした肺癌の化学療法に関する研究 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Lewis lung carcinoma in an advanced stage was evaluated as a model of human lung cancer for screening drugs and drug combinations. The tumor was fairly resistant to drugs when therapy was started 7 days after tumor transplantation. Among the drugs which have been used conventionally in the treatment of human lung cancer, cyclophosphamide was the only are distinctly active against the tumor. BCNU, a nitrosourea, was fairly active; however, adriamycin, methotrexate and vincristine were only marginally active. The drug sensitivity of the experimental tumor in an advanced stage appeared to correlate well with that of human lung cancer, especially in the case of non-small cell lung cancer, which is regarded as a representative of drug-resistant human tumors. As for the screening of new drugs, ifosfamide, an analogue of cyclophosphamide, was as equally active as the mother compound. ACNU, a new nitrosourea, was more effective than the mother compound, BCNU. These drugs have proved to be active against human lung cancer, indicating that the advanced Lewis lung carcinoma provided a drug activity spectrum closely analogous to human lung cancer. However, in the case of cis-dichlorodiammineplatinum (Ⅱ), a considerable dissociation was observed between the animal model and human lung cancer: the drug, which was regarded to be inactive in the animal model, has recently shown clinical activity against small cell and non-small cell lung cancer. The effect of drug combinations was distinct only in the case of cyclophosphamide plus ACNU, or ifosfamide plus ACNU, suggesting the usefulness of these drug combinations in the treatment of human lung cancer. en-copyright= kn-copyright= en-aut-name=MurakamiNaoki en-aut-sei=Murakami en-aut-mei=Naoki kn-aut-name=村上直樹 kn-aut-sei=村上 kn-aut-mei=直樹 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=Lewis lung carcinoma kn-keyword=Lewis lung carcinoma en-keyword=cyclophosphamide kn-keyword=cyclophosphamide en-keyword=ifosfamide kn-keyword=ifosfamide en-keyword=多剤併用 kn-keyword=多剤併用 END start-ver=1.4 cd-journal=joma no-vol=100 cd-vols= no-issue=5-6 article-no= start-page=621 end-page=631 dt-received= dt-revised= dt-accepted= dt-pub-year=1988 dt-pub=1988 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on the treatment and management of malignant lymphoma Part 2. Combination chemotherapy for diffuse large-cell non-Hodgkin's lymphoma superiority of adriamycin combination kn-title=悪性リンパ腫の診断と治療に関する研究 第2編 びまん性大細胞型非ポジキンリンパ腫におけるAdriamycinを含む多剤併用療法の有用性に関する検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=A comparison was made between the therapeutic outcome of patients with diffuse large-cell non-Hodgkin's lymphoma treated with combination chemotherapy containing adriamycin (adriamycin regimen) and those treated with combination chemotherapy not containing adriamycin (non-adriamycin regimen). All the patients had no prior therapy, and there were no differences in any other background factors between the two treatment groups. Of 32 patients on the non-adriamycin regimen, 19 (59%) achieved complete response (CR) and 12 (38%) achieved partial response (PR). Of 20 patients on the adriamycin regimen, 14 (70%) achieved CR and 6 (30%) achieved PR. For those on the non-adriamycin regimen, the median duration of CR was 10 months, the projected 5-year relapse-free rate was 27%; the median survival time for all patients was 1 year 7 months; and the projected 5-year survival rate was 24%. For those on the adriamycin regimen, a median duration of CR was not reached, the projected 5-year relapse-free rate was 85%; the median survival time for all patients was 1 year 11 months; and the projected 5-year survival rate for all patients was 58%. These results show the superiority of combination chemotherapy containing adriamycin, indicating that adriamycin is a essential agent for the initial induction chemotherapy for the large-cell type of non-Hodgkin's lymphoma. en-copyright= kn-copyright= en-aut-name=YoshidaMitsuo en-aut-sei=Yoshida en-aut-mei=Mitsuo kn-aut-name=吉田光雄 kn-aut-sei=吉田 kn-aut-mei=光雄 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=非ホジキンリンパ腫 kn-keyword=非ホジキンリンパ腫 en-keyword=adriamycin kn-keyword=adriamycin en-keyword=多剤併用療法 kn-keyword=多剤併用療法 END start-ver=1.4 cd-journal=joma no-vol=103 cd-vols= no-issue=11-12 article-no= start-page=1301 end-page=1310 dt-received= dt-revised= dt-accepted= dt-pub-year=1991 dt-pub=1991 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on chemotherapy for small cell lung cancer Part 1. Reversal of adriamycin resistance in human small cell lung cancer cells in culture kn-title=肺小細胞癌の化学療法に関する研究 第1編 Adriamycin 耐性ヒト肺小細胞癌細胞株の耐性解除に関する検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Using adriamycin-resistant human small cell lung cancer cells (SBC-3/ADM), which were 30-fold more resistant to adriamycin than the parent cells (SBC-3), the ability of membrane-modifying agents to overcome the drug resistance was analyzed by a soft agar clonogenic assay. SBC-3/ADM was not circumvented by hyperthermia of 42℃ or amphotericin B at a concentration of 50μ M. Verapamil did not enhance the adriamycin cytoxicity in the SBC-3 cells at a concentration of 10μ M, but a 3.2-fold increase in the drug effect occurred in the SBC-3/ADM cells in terms of LD(70). The efflux of intracellular [H(3)] daunomycin from SBC-3/ADM cells was inhibited by verapamil, while the inhibition did not occur in the parent cells. Furthermore, quinidine (50μ M), cepharanthin (10μ M) and chloroquine (50μ M) enhanced the adriamycin cytotoxicity in the SBC-3/ADM cells. These findings suggest that some membrane-modifying agents could partially overcome the acquired resistance to adriamycin in human small cell lung cancer. en-copyright= kn-copyright= en-aut-name=YamashitaHidetoshi en-aut-sei=Yamashita en-aut-mei=Hidetoshi kn-aut-name=山下英敏 kn-aut-sei=山下 kn-aut-mei=英敏 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=human small cell lung cancer cells in culture kn-keyword=human small cell lung cancer cells in culture en-keyword=ADM resistant subline kn-keyword=ADM resistant subline en-keyword=reversal of resistance kn-keyword=reversal of resistance END start-ver=1.4 cd-journal=joma no-vol=104 cd-vols= no-issue=5-6 article-no= start-page=677 end-page=686 dt-received= dt-revised= dt-accepted= dt-pub-year=1992 dt-pub=1992 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=The relationship between thermotolerance and changes of cell cycle after hyperthemia in culture cells kn-title=培養細胞における細胞周期の変動と熱耐性の発現に関する研究 en-subtitle= kn-subtitle= en-abstract= kn-abstract=To examine the apperance of thermotolerance in a random growing population, changes in cell cycle fractions after hyperthermia, thermosensitivity and thermotolerance during the cell cycle were studied in mouse NIH3T3 cell. Progression of S phase cells was disturbed slightly and a marked increase of G(2) + M cells fraction (G(2)-block) was observed after heating (43℃ 60min, 44℃ 20min, 40min, and 45℃ 10 min). Maximun thermotolerance after 10, 20, and 30min at 45℃ appeared at 6, 12 and 45 hrs after heating, respectively. G(0) cell stimulated with frsh medium containing 10% calf serum, entered into the G(1) and S phase. When these cells were exposed to 45℃ for 30min at each point after stimulation, the thermosensitivity to heating changed with progression of time after the stimulation. S phase cells showed the highest thermosensitivity. Thermotolerance of S phase was larger than that of G(1) phase. The mechanisms involved in the appearance of thermotolerance were discussed. en-copyright= kn-copyright= en-aut-name=MatsubaraShinichiro en-aut-sei=Matsubara en-aut-mei=Shinichiro kn-aut-name=松原伸一郎 kn-aut-sei=松原 kn-aut-mei=伸一郎 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部放射線医学教室 en-keyword=熱耐性 kn-keyword=熱耐性 en-keyword=細胞周期 kn-keyword=細胞周期 en-keyword=培養細胞 kn-keyword=培養細胞 en-keyword=ハイパーサーミア kn-keyword=ハイパーサーミア END start-ver=1.4 cd-journal=joma no-vol=104 cd-vols= no-issue=9-10 article-no= start-page=905 end-page=913 dt-received= dt-revised= dt-accepted= dt-pub-year=1992 dt-pub=199210 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on cell biology and chemotherapy of lung cancer using tissue culture techniques Part 2. Biological characteristics of five newly established small cell lung cancer cell lines kn-title=組織培養法を用いた肺癌の細胞生物学並びに治療に関する研究 第2編 肺小細胞癌細胞株の樹立とその生物学的特徴 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Five small cell lung cancer (SCLC) cell lines in culture were established and designated as SBC-1, 2, 3, 4 and 5. SBC-1, 2, 4 and 5 were derived from tumors of intermediate cell histology, and SBC-3 was from a tumor of oat cell histology. All the cell lines represented a characteristic cytomorphology of SCLC when examined by papanicolaou staining and by electron microscopy. Their biological characterstics such as doubling time, clonogenic activity, heterotransplantability in nude mice, and capacity of hormone production in culture revealed that each cell line had a distinct biological feature. The SCLC cell lines reported here would be useful as a tool for cellular pharmacology of new drugs and drug resistance. en-copyright= kn-copyright= en-aut-name=KishimotoNobuyasu en-aut-sei=Kishimoto en-aut-mei=Nobuyasu kn-aut-name=岸本信康 kn-aut-sei=岸本 kn-aut-mei=信康 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=small cell lung cancer kn-keyword=small cell lung cancer en-keyword=cell line kn-keyword=cell line en-keyword=characterization kn-keyword=characterization END start-ver=1.4 cd-journal=joma no-vol=104 cd-vols= no-issue=9-10 article-no= start-page=897 end-page=904 dt-received= dt-revised= dt-accepted= dt-pub-year=1992 dt-pub=199210 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on cell biology and chemotherapy of lung cancer using tissue culture techniques Part 1. Drug sensitivity test in lung cancer using human tumor clonogenic assay kn-title=組織培養法を用いた肺癌の細胞生物学並びに治療に関する研究 第1編 Human Tumor Clonogenic Assay を用いた制癌剤感受性試験の検討―肺癌を中心として― en-subtitle= kn-subtitle= en-abstract= kn-abstract=The selection of a series of effective drugs for individual patients in advance of drug therapy should increase the success of cancer chemotherapy. The human tumor clonogenic assay was evaluated as a drug sensitivity test mainly in patients with lung cancer. Tumor cells from malignant pleural effusion, tumor-positive bone marrow aspirates, and tumor tissues from the primary or metastases were used as sepcimens. Prior to plating, tumor cells were exposed to 4-hydroperoxy ifosfamide, adriamycin, mitomycin C, methotrerxate, and cisplatin for one hour at graded concentrations which were achievable in man. Of 151 specimens tested, 93(62%) yielded at least 5 colonies in the control plates containing no durgs. Colony growth (≧5/plate) was seen in 80% of squamous cell carcinoma, in 73% of small cell carcinoma, in 62% of adenocarcinoma, and in 40% of large cell carcinoma. Among the 93 specimens with colony growth, 62 yielded more than 30 colonies in the control plates and were put in force for drug sensitivity testing. Of 37 instances in which the clinical response to a certain drug was examined, 34(92%) showed an in vitro-in vivo correlation, showing a true positive rate of 57% and a true negative rate of 100%. In summary, the human tumor clonogenic assay would be an excellent technique for testing the drug sensitivity of the tumor in individual patients tumor. en-copyright= kn-copyright= en-aut-name=KishimotoNobuyasu en-aut-sei=Kishimoto en-aut-mei=Nobuyasu kn-aut-name=岸本信康 kn-aut-sei=岸本 kn-aut-mei=信康 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=human tumor clonogenic assay kn-keyword=human tumor clonogenic assay en-keyword=drug sensitivity kn-keyword=drug sensitivity en-keyword=lung cancer kn-keyword=lung cancer END start-ver=1.4 cd-journal=joma no-vol=106 cd-vols= no-issue=5-6 article-no= start-page=587 end-page=598 dt-received= dt-revised= dt-accepted= dt-pub-year=1994 dt-pub=1994 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Acute leukemia in the aged : Chemotherapeutic effect of aclarubicin on acute nonlymphocytic leukemia kn-title=高齢者白血病の治療に関する研究 en-subtitle= kn-subtitle= en-abstract= kn-abstract=To investigate clinical management of acute nonlymphocytic leukemia (ANLL) in the aged, the chemotherapeutic effects of aclarubicin (ACR) were studied in 20 ANLL patients (M1 5, M2 3, M4 5, M5b 6, M6 1). All patients were over 70 years old. The ratio of male to female was 16 : 4 and age ranged from 70 to 84 years old (mediam : 76y/o). Nineteen patients were untreated, one case had previous treament and 2 patients showed hypoplastic marrow on admission. ACR was administered by intravenous drip infusion at a dose of 14mg/m2/day for 7-10 days and repeated after recovery of myelosuppression. Eight patients (40%) obtained complete remission (CR) : 1 of 5 M1 (20%), 3 of 5 M4 (60%), 4 of 6 M5b (66.7%) and none of M2 or M6. CR ratio was 44% in 18 typical ANLL patients excluding the two patients with hypoplastic marrow, who did not attain CR. The duration of CR was from 1.3 to 11.3 months (median : 7.3 months) and survial time ranged from 6.6 to 15.6 months (median : 11.8 months) in patients with CR. Although side effects on the digestive system such as nausea, vomiting and anorexia were seen in 11 of 20 patients, these effects were controllable. None of the patients showed cardiac toxicity. ACR is expected to be useful in the clinical management of ANLL in patients over 70 years old, especially for M4 and 5 in the aged. en-copyright= kn-copyright= en-aut-name=NakamuraTohru en-aut-sei=Nakamura en-aut-mei=Tohru kn-aut-name=中村達 kn-aut-sei=中村 kn-aut-mei=達 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=acute leukemia in the aged kn-keyword=acute leukemia in the aged en-keyword=antileukemic chemotherapy kn-keyword=antileukemic chemotherapy en-keyword=aclarubicin kn-keyword=aclarubicin END start-ver=1.4 cd-journal=joma no-vol=105 cd-vols= no-issue=11-12 article-no= start-page=1019 end-page=1030 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=19931231 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on chemotherapy for malignant lymphoma Part 2. Evaluation of anticancer drug combination on hematologic malignant cell lines using median effect analysis kn-title=悪性リンパ腫の化学療法に関する研究 第2編 血液腫瘍細胞に対する in vitro の薬剤併用効果：Median effect analysis による検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=To establish an effective combination chemotherapy for hematologic malignancies, the combined effects of four anthracycline-anthraquinones and five other drugs were assessed in vitro. The anthracycline-anthraquinones were adriamycin (ADM), aclarubicin (ACR), THP-adriamycin (THP-ADM), mitoxantrone (MXT) and five other drugs were 4-hydroperoxycyclophosphamide (4HO(2)-CTX), cytarabine (Ara-C), vincristine (VCR), etoposide (ETP), cisplatin (CDDP). Median effect analysis presented by Chou and Talalay was used to assess the combined effects of these drugs on two cell lines (HL-60 and Raji). In addition, the ratio of maximal tolerable dose (MTD) to the dose that produced 50% growth inhibition (Dm) was calculated to estimate the clinical activity of each drug. Data of MTD/Dm indicated that THP-ADM and MXT might be clinically superior to ADM and ACR. The results of median effect analysis shown by a combination index were as follows : As to HL-60 cells that were derived from acute promyelocytic leukemia cells, synergistic effects were seen in the combination of ACR and Ara-C, THP-ADM and CDDP, MXT and 4HO2-CTX, MXT and Ara-C, MXT and VCR, MXT and ETP, indicating that MXT showed efficient synergistic effects when combined with other drugs. As to Raji cells that were derived from Burkitt's lymphoma cells, synergistic effects were observed in the combinations of ADM and ETP, ADM and CDDP, ACR and VCR,THP-ADM and VCR, THP-ADM and ETP, THP-ADM and CDDP, MXT and VCR, indicating that THP-ADM showed efficient synergistic effects when combined with other drugs. en-copyright= kn-copyright= en-aut-name=UenoKunio en-aut-sei=Ueno en-aut-mei=Kunio kn-aut-name=上野邦夫 kn-aut-sei=上野 kn-aut-mei=邦夫 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=median effect analysis kn-keyword=median effect analysis en-keyword=in vitro 薬剤併用効果 kn-keyword=in vitro 薬剤併用効果 END start-ver=1.4 cd-journal=joma no-vol=106 cd-vols= no-issue=5-6 article-no= start-page=493 end-page=503 dt-received= dt-revised= dt-accepted= dt-pub-year=1994 dt-pub=1994 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on malignant lymphoma Part 1. Second malignant neoplasms in patients with malignant lymphoma after chemotherapy kn-title=悪性リンパ腫の病態と治療に関する研究 第1編 悪性リンパ腫化学療法後の2次癌発症についての検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=The risk of a second malignancy was analyzed in 23 patients with Hodgkin's disease (HD) and 177 with non-Hodgkin's lymphoma (NHL) who were initially treated with combination chemotherapy between 1976 and 1990. Among these patients, 3 cases of gastric cancer, 2 cases of lung cancer, 2 cases of hepatoma, one case of colon cnacer, one case of cholangiocarcinoma and one case of acute myeloblastic leukemia were subsequently observed. Median age at diagnosis of lymphoma was 64 years in patients who developed subsequent malignancies but was 9 years higher than that for the entire lymphoma group. Median interval from srart of chemotherapy to the appearance of second malignancy was 43.9 years and ranged from 1.9 years to 8.8 years. The 7-year cumulative risk of second malignancy in HD and NHL were 7.7% and 11.7%, respectively. In Hodgkin's disease, the incidence of stomach and lung cancers was significantly greater than expected incidence calculated on the basis of age-adjusted person-years. In non-Hodgkin's lymphoma, the incidence was also greater than expected for all malignancies except stomach cancer. This indicater that the incidence of solid malignancy as well as leukemia is higher in lymphoma patients after chemotherapy than in the general population. en-copyright= kn-copyright= en-aut-name=TagawaShinya en-aut-sei=Tagawa en-aut-mei=Shinya kn-aut-name=田川真也 kn-aut-sei=田川 kn-aut-mei=真也 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=malignant lymphoma kn-keyword=malignant lymphoma en-keyword=chemotherapy kn-keyword=chemotherapy en-keyword=second primary malignancy kn-keyword=second primary malignancy END start-ver=1.4 cd-journal=joma no-vol=105 cd-vols= no-issue=5-6 article-no= start-page=489 end-page=498 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=1993 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Clinical trial of enhancement method fro ultrasonographic diagnosis of thyroid nodules kn-title=結節性甲状腺腫の超音波診断における Enhancement 法の試み en-subtitle= kn-subtitle= en-abstract= kn-abstract=Enhancement in thyroid ultrasonography was investigated with thyroid lymphography by injection of Lipiodol into thyroid nodules in 50 patients. On plain thyroid ultrasonography (PU), the echo levels of normal and tumorous portions of the thyroid glands were evaluated. Then, the echo level ratios (P-N/T) were calculated. Moreover, by the same method, the echo level ratios between normal and tumorous portions of the thyroid glands were culculated 6 hours after Lipiodol injection (E-N/T), when the greatest enhancement was anticipated. The mean value of P-N/T was 1.305, and that of E-N/T was 1.474. The echo level ratio was significantly elevated in the enhancement method (p<0.0014). We concluded that the enhancement is obtained with Lipiodol injection into the normal portion of the thyroid glands, regardless of whether the tumor is benign or malignant and with or without cystic degeneration. This method is useful in promoting quality and location diagnosis of thyroid nodules. N : echo level value in the normal portion of thyroid gland T : echo level value in the tumorous portion of thyroid gland N/T : echo level raito en-copyright= kn-copyright= en-aut-name=TakeuchiRyuzo en-aut-sei=Takeuchi en-aut-mei=Ryuzo kn-aut-name=竹内龍三 kn-aut-sei=竹内 kn-aut-mei=龍三 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二外科学教室 en-keyword=超音波診断 kn-keyword=超音波診断 en-keyword=結節性甲状腺腫 kn-keyword=結節性甲状腺腫 en-keyword=Enhancement kn-keyword=Enhancement en-keyword=甲状腺リンパ造影 kn-keyword=甲状腺リンパ造影 en-keyword=エコーレベル kn-keyword=エコーレベル END start-ver=1.4 cd-journal=joma no-vol=105 cd-vols= no-issue=11-12 article-no= start-page=1009 end-page=1017 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=19931231 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on chemotherapy for malignant lymphoma Part 1. Salvage chemotherapy for non-Hodgkin's lymphoma ; MEPP : Combination of mitoxantrone, etoposide, cisplatin and prednisolone kn-title=悪性リンパ腫の化学療法に関する研究 第1編 Mitoxantrone, Etoposide, Cisplatin, Prednisolone 併用療法(MEPP) による non-Hodgkin's lymphoma の salvage 治療の検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Twenty six patients with non-Hodgkin's lymphoma (NHL), who failed to achieve complete remission or had relapsed after conventional chemotherapy (CHOP or CHOP-Bleo) were treated with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP). Of 24 patients evaluated, five (21%) achieved complete remission and seven (29%) responded partially. The median duration of remission was 25 weeks, 38 weeks for complete responders (CRs), 24 weeks for partial responders (PRs). The median survival time after initiation of therapy was 93 weeks for CRs, 50 weeks for PRs and 25 weeks for non-responders (NRs). The difference in survival time between CRs and NRs was statistically significant. Myelosuppression was the major dose-limiting toxicity ; WBC nadir below 1,000/μl occurred in 66.2% of evaluable courses. Two patients with bone marrow involvement died of infection due to granulocytopenia. Renal toxicity of cisplatin was moderate and there was no cardiotoxicity of mitoxantrone detected. Despite severe myelotoxicity, these results indicate that MEPP regimen is useful as a salvage therapy for relapsed or refractory NHL. en-copyright= kn-copyright= en-aut-name=UenoKunio en-aut-sei=Ueno en-aut-mei=Kunio kn-aut-name=上野邦夫 kn-aut-sei=上野 kn-aut-mei=邦夫 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=非ホジキンリンパ腫 kn-keyword=非ホジキンリンパ腫 en-keyword=salvage 治療 kn-keyword=salvage 治療 END start-ver=1.4 cd-journal=joma no-vol=105 cd-vols= no-issue=5-6 article-no= start-page=437 end-page=445 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=1993 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Clinical studies on atypical leukemia Part 2. Clinical effects of low-dose (4)N-Behenoyl-β-D-Arabinofuranosylcytosine(BHAC) therapy on atypical leukemia kn-title=非定型的白血病の病態並びに治療に関する研究 第2編 非定型的白血病の治療に関する検討：(4)N-behenoyl-1-β-D-arabinofuranosyl-cytosine(BHAC) 少量療法の臨床効果 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Therapeutic effects of low-dose (4)N-Behenoyl-β-D-Arabinofuranosylcytosine(BHAC) on 52 patients with hypoplastic leukemia were analyzed to establish the optimal clinical management of hypoplastic leukemia. Among 8 patients treated with a low-dose (4)N-Behenoyl-β-D-Arabinofuranosyl cytosine (LD-BHAC) regimen, in which 50mg BHAC was administered daily intravenously by one-hour drip infusion for 14 days, 4 patients obtained complete remission (CR) and 2 patients obtained partial remission (PR). The response rate (CR+PR) was 75%. The responders were all over 65 years old. Although hematological toxicities and adverse effects on the digestive system such as anorexia and nausea were observed, they were all controllable by conventional treatments. The serum concentrations of ara-C were measured in 4 patients. Serum ara-C reached the peak concentration, 3.62-18.9 ng/ml (mean : 11.74 ng/ml), at the cessation of BHAC infusion, and a serum ara-C level of 2.75-4.89 ng/ml (mean : 3.54 ng/ml) was still present 6 hours after the cessation of infusion. Among 44 patients hospitalized before 1984, 27 patients were treated with blood transfusion and /or single antileukemic agent and 17 patients received combination chemotherapeutic regimens. Only 8 of 44 patients attained CR. The responders were all below 65 years old, and except for one patient, received combination chemotherapy. These results suggest that LD-BHAC therapy is useful in the clinical management of hypoplastic leukemia as a remission induction chemotherapy. en-copyright= kn-copyright= en-aut-name=NakadaHiroshi en-aut-sei=Nakada en-aut-mei=Hiroshi kn-aut-name=仲田浩之 kn-aut-sei=仲田 kn-aut-mei=浩之 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=atypical leukemia kn-keyword=atypical leukemia en-keyword=therapy of hypoplastic leukemia kn-keyword=therapy of hypoplastic leukemia en-keyword=low dose behenoyl-ara-C therapy kn-keyword=low dose behenoyl-ara-C therapy en-keyword=behenoyl-ara-C kn-keyword=behenoyl-ara-C END start-ver=1.4 cd-journal=joma no-vol=106 cd-vols= no-issue=3-4 article-no= start-page=401 end-page=413 dt-received= dt-revised= dt-accepted= dt-pub-year=1994 dt-pub=1994 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Kinetics of heat shock protein 72 in HeLa cells after treatment with heating and/or anticancer agents analyzed by a laser cytometer kn-title=レーザーサイトメーターを用いたheat shock protein 72の加温および抗癌剤添加による動態の検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Heat shock proteins (HSPs) are regarded as the proteins most related to the development of thermotolerance. Recently, not only their role in thermotolerance, but also their role in resistance to anticancer agents is gathering concern. In this study, the kinetics of hsp 72 in HeLa cells treated with heating and/or anticancer agents were studied. Hsp 72 was immuno-stained by the indirect fluorescent technique using a monoclonal anti-hsp 72 antibody (Amer-sham). The staining pattern was observed and analyzed using a laser cytometer, ACAS 570 (Meridian). Hsp 72 was normally found in the cytoplasm at 37℃ and moved rapidly into the nucleus with heating at 43℃ for 2 hours. It then returned to the cytoplasm 4 to 6 hours after heating. The hsp 72 content reached a peak at 8 hours after heating. Hsp 72 was induced in all cells treated with cisplation, adriamycin, peplomycin, or etoposide for 48 hours. In the cells treated with both heating at 43℃ for 2 hours and these anticancer agents, hsp 72 induction was most suppressed by adriamycin. However, translocation of hsp 72 to the nucleus was specific for heating and was not affected by the anticancer agents. By laser cytometry the intracellular localization of hsp 72 and the changes of its content were simultaneously detected, Moreover, the change pattern of hsp 72 content measured by laser cytomtry coincided with that measured by the Western blotting procedure. en-copyright= kn-copyright= en-aut-name=SawaiHideaki en-aut-sei=Sawai en-aut-mei=Hideaki kn-aut-name=澤井秀秋 kn-aut-sei=澤井 kn-aut-mei=秀秋 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部産科婦人科学教室 en-keyword=レーザーサイトメーター kn-keyword=レーザーサイトメーター en-keyword=heat shock proteinｎ kn-keyword=heat shock proteinｎ en-keyword=抗癌剤 kn-keyword=抗癌剤 END start-ver=1.4 cd-journal=joma no-vol=106 cd-vols= no-issue=3-4 article-no= start-page=379 end-page=389 dt-received= dt-revised= dt-accepted= dt-pub-year=1994 dt-pub=1994 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Chemothrapy of small cell lung cancer : Comparative phase Ⅱ study of CAV-PVP hybrid regimen and CAV-PVP sequential regimen in patients with small cell lung cancer(SCLC) kn-title=肺小細胞癌の化学療法の関する研究―肺小細胞癌に対するCAV-PVP hybrid療法とCAV-PVP sequential療法の無作為化比較試験― en-subtitle= kn-subtitle= en-abstract= kn-abstract=One hundred and forty three patients with previously untreated SCLC were randomly allocated to receive either the CAV-PVP hybrid (Hyb) regimen or CAV-PVP sequential(Seq) regimen between November 1987 and October 1992. The Hyb regimen consisted of CAV (cyclophosphamide 700mg/㎡,iv,day 1 ; adriamycin 30mg/㎡,iv,day 1 ; and vincristine 1.4mg/㎡,iv,day 1) and PVP (cisplatin 60mg/㎡,iv,day 8 ; and etoposide 100mg/㎡,iv,days 8 and 9), and was repeated up to 6 cycles at 4-week intervals. The Seq regimen consisted of an initial 3 cycles of CAV (cyclophosphamide 700mg/㎡,iv,days 1 and 8 ; adriamycin 30mg/㎡,iv days 1 and 8 ; and vincristine 1.4mg/㎡,iv,day 8 ; and vincristine 1.4mg/㎡,iv days 1 and 8) followed by 3 cycles of PVP (cisplatin 60mg/㎡,iv,days 1 and 8 ; and etoposide 100mg/㎡,iv,days 1, 2, 8 and 9) at 4-week intervals. For patients with limited disease (LD), thoracic irradiation at a dose of 50 Gy was given after a maximal response with chemotherapy, and LD patients achieving a complete response (CR) received prophylactic cranial irradiation at a dose of 30 Gy. For the LD patients, the overall response rate was 97% for the Hyb regimen with a CR rate of 59% and 100% for the Seq regimen with a CR rate of 45%. For the patients with extensive disease (ED), the overall response rate was 94% for the Hyb regimen with a CR rate of 21% and 78% for the Seq regimen with a CR rate of 16%. The median survival time (MST) for the LD patients was 17.9 months for the Hyb group and 20.9 months for the Seq group, and the MST for the ED patients was 9.7 months for the Hyb group and 12.2 months for the Seq group. The 3-year survival rate for the LD patients was 21.9% for the Hyb group and 18.8% for the Seq group. There was a trend favoring the Hyb regimen in terms of overal response rate, CR rate, and 3-year survival rate for the LD patients as well, but there was no significant difference in survival between the two treatment groups. Hematologic toxicity was the major dose-limiting toxicity, but it was generally well-tolerated in both treatment groups. These findings indicate that both Hyb and Seq regimens are equally effective for the prolongation of life in patients with SCLC. en-copyright= kn-copyright= en-aut-name=KameiHaruhito en-aut-sei=Kamei en-aut-mei=Haruhito kn-aut-name=亀井治人 kn-aut-sei=亀井 kn-aut-mei=治人 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=肺小細胞癌 kn-keyword=肺小細胞癌 en-keyword=CAV-PVP hybrid療法 kn-keyword=CAV-PVP hybrid療法 en-keyword=CAV-PVP sequential療法 kn-keyword=CAV-PVP sequential療法 en-keyword=無作為化比較試験 kn-keyword=無作為化比較試験 en-keyword=dose-intensity kn-keyword=dose-intensity END start-ver=1.4 cd-journal=joma no-vol=105 cd-vols= no-issue=11-12 article-no= start-page=891 end-page=901 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=19931231 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Alternating CHOPB-POEMB chemotherapy for intermediate- and high-grade non-Hodgkin's lymphomas kn-title=非ホジキンリンパ腫における CHOPB-POEMB 交替療法に関する研究―中・高悪性度の組織型についての検討― en-subtitle= kn-subtitle= en-abstract= kn-abstract=Between 1986 and 1991, 45 patients with intermediate- or high-grade non-Hodgkin's lymphoma, including 30 patient with large cell lymphoma (including both diffuse large cell and large cell, immunoblastic), were treated with CHOPB-POEMB chemotherapy. The regimen consisted POEMB (a combination of prednisolone, vincristine, etoposide and bleomycin) alternating every 3 weeks with a variant of CHOP-Bleo. None of the patients had received prior chemotherapy. The overall complete response (CR) rate was 80% and 20 patients (57%) were disease free for a median follow up time of 48 months. In cases of large cell lymphoma, the CR rate and disease free rate were 73% and 65%, respectively. Toxic effects were well-tolerated. Alternating CHOPB-POEMB was useful for treatment of intermediate- or high-grade non-Hodgkin's lymphomas. en-copyright= kn-copyright= en-aut-name=MizutaJun en-aut-sei=Mizuta en-aut-mei=Jun kn-aut-name=水田潤 kn-aut-sei=水田 kn-aut-mei=潤 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=non-Hodgkin's lymphoma kn-keyword=non-Hodgkin's lymphoma en-keyword=chemotherapy kn-keyword=chemotherapy END start-ver=1.4 cd-journal=joma no-vol=106 cd-vols= no-issue=3-4 article-no= start-page=187 end-page=198 dt-received= dt-revised= dt-accepted= dt-pub-year=1994 dt-pub=1994 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Studies on the effect of chemotherapy for multiple myeloma with analysis of bone lesion Part 1. Combination chemotherapy effect for multiple myeloma with aclarubicin, vincristine, cyclophoshamide and prednisolone including analysis on prognostic factors kn-title=多発性骨髄腫における化学療法の治療効果と骨病変に関する臨床的検討 第1編 多発性骨髄腫における Aclarubicin, Vincristine, Cyclophospamide, Prednisolone 併用療法における治療効果と予後因子に関する臨床的検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Sixty-one patients with multiple myeloma consisting of 45 previously untreated and 16 previously treated patinets were given combination therapy of aclarubicin, vincristine, cydlo-phosphmide and prednisolone. The overall response rate evaluated by 50% reduction in M-protein was 47%. The median survival time 40 months, which indicated satisfactory effectiveness. The previously untreated patients with stage Ⅲ disease had a much higher response rate (58%) than those with stage Ⅱ (33%). There was no significant difference in the 5-year survival between the patients with stage Ⅲ (33%) and stage Ⅱ (33%) disease. These findings indicate the effectiveness of the therapy for stage Ⅲ cases, especially patients with stage Ⅲ disease under good control showed long-term survival of more than 5 years. Marked symptomatic inpovement was observed in 77%. For patients with advanced bone lesion the therapy was also valuable. The multivariate anaysis (proportional hazard model of Cox) of individual biochemical and clinical variables showed that the tumor was the most significant variable related to prognos-tic factor followed by good and poor control and serum calcium level. Hematologic toxicity, infection, nausea and vomiting occurred frequently, although the incidence of ECG change (9%) was low and transient. en-copyright= kn-copyright= en-aut-name=IzumiKen en-aut-sei=Izumi en-aut-mei=Ken kn-aut-name=和泉健 kn-aut-sei=和泉 kn-aut-mei=健 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=multiple myeloma kn-keyword=multiple myeloma en-keyword=combination chemotherapy kn-keyword=combination chemotherapy en-keyword=prognostic factor kn-keyword=prognostic factor en-keyword=multivariative analysis kn-keyword=multivariative analysis en-keyword=bone status kn-keyword=bone status END start-ver=1.4 cd-journal=joma no-vol=105 cd-vols= no-issue=1-2 article-no= start-page=81 end-page=86 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=19930227 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Evaluation of anthracycline-anthraquinone analogues in the treatment of lung cancer using colony assay Part 2. Comparison of cytotoxic effect of anthracycline-anthraquinone analogues in tumor specimens obtained from lung cancer patients kn-title=Colony assay 法を用いた肺癌化学療法における Anthracycline-anthraquinone 系薬剤の有効性に関する研究 第2編 ヒト肺癌腫瘍材料における Anthracycline-anthraquinone 系薬剤の抗腫瘍効果の比較 en-subtitle= kn-subtitle= en-abstract= kn-abstract=The drug sensitivity test using a human tumor clonogenic assay is an in vitro technique providing a high degree of accuracy for predicting the clinical response to anticancer drugs. The author applied this assay to compare the in vitro anticancer efffects of four anthracycline-anthraquinone analogues against lung cancer. The drugs tested in the present study were adriamycin(ADM), aclarubicin(ACR), THP-adriamycin(THP-ADM) and mitoxantrone(MIT). A tumor was defined as sensitive, when the suviving fraction of colony-forming units was reduced 70% or more at a clinically achievable plasma concentration of these drugs in man. Tumor specimens from 100 individual patients were placed in culture. Forty-five specimens (45%) formed enough colonies to test durg sensitivity. Fourteen of the 31 specimens(45%) tested were found to be sensitive fof ACR, 15 of 35(43%) for THP-ADM, 10 of 30(33%) for MIT, and 7 of 43(16%) for ADM. These fingings indicated that the activity of ACR and THP-ADM is stronger than that of ADM in the treatment of lung cancer. en-copyright= kn-copyright= en-aut-name=NumataTakeyuki en-aut-sei=Numata en-aut-mei=Takeyuki kn-aut-name=沼田健之 kn-aut-sei=沼田 kn-aut-mei=健之 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=肺癌腫瘍材料 kn-keyword=肺癌腫瘍材料 en-keyword=colony assay kn-keyword=colony assay en-keyword=anthracycline kn-keyword=anthracycline en-keyword=anthraquinone kn-keyword=anthraquinone END start-ver=1.4 cd-journal=joma no-vol=105 cd-vols= no-issue=1-2 article-no= start-page=73 end-page=80 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=19930227 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Evaluation of anthracycline-anthraquinone analogues in the treatment of lung cancer using colony assay Part 1. Comparison of antitumor activity of anthracycline-anthraquinone analogues in human lung cancer cell lines kn-title=Colony assay 法を用いた肺癌化学療法における Anthracycline-anthraquinone 系薬剤の有効性に関する研究 第1編 ヒト肺癌細胞株に対する Anthracycline-anthraquinone 系薬剤の殺細胞効果の比較 en-subtitle= kn-subtitle= en-abstract= kn-abstract=In an attempt to evaluate the antitumor activity of new anthracycline-anthraquinone analogues ; aclarubicin (ACR), tetrahydropyranyl adriamycin (THP-ADM), and mitoxantrone(MIT), these analogues were compared with adriamycin(ADM) in terms of 70% lethal dose by colony assay using five human lung cancer cell lines, which had been established and maintained in our laboratory. The human lung cancer cell lines tested were EBC-1, an epidermoid cancer cell line, ABC-1, an adenocarcinoma cell line, and SBC-1, -2, and -3, small cell cancer cell lines. In general, the EBC-1 established from a patient tumor showing resistance to ADM was the least sensitive to the drugs tested, and SBC-3 established from a patient tumor with no prior chemotherapy was the most sensitive to the drugs. In antitumor activity, both ACR and THP-ADM appeared to be superior to ADM and MIT, suggesting the clinical usefulness of these drugs in the treatment of lung cancer. en-copyright= kn-copyright= en-aut-name=NumataTakeyuki en-aut-sei=Numata en-aut-mei=Takeyuki kn-aut-name=沼田健之 kn-aut-sei=沼田 kn-aut-mei=健之 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=肺癌細胞株 kn-keyword=肺癌細胞株 en-keyword=colony assay kn-keyword=colony assay en-keyword=anthracycline kn-keyword=anthracycline en-keyword=anthraquinone kn-keyword=anthraquinone END start-ver=1.4 cd-journal=joma no-vol=113 cd-vols= no-issue=1 article-no= start-page=1 end-page=16 dt-received= dt-revised= dt-accepted= dt-pub-year=2001 dt-pub=20010428 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Establishment of an adriamycin-resistant human bladder cancer cell line (T-24/ADM) and analysis of the mechanism of resistance kn-title=Adriamycin 耐性ヒト膀胱癌培養細胞株の樹立と耐性機序に関する研究 en-subtitle= kn-subtitle= en-abstract= kn-abstract=A human bladder cencer cell line resistant to adriamycin (ADM), T-24/ADM was establishied in vitro by exposing T-24 parent cells to a progressively higher concentration of the drug over an 18 month period. The T-24/ADM was 34.9 times more resistant to ADM than the T-24 parent. The T-24/ADM exhibited cross resistance to ADM derivatives, vinca alkaloid (vindesine, vincristine), etoposide and SN-38, but collateral sensitivity to methotrexate. The biological and biochemical characteristics of T-24/ADM were examined in terms of ADM-resistance. Although a flow cytometric analysis showed that Pglycoprotein is not expressed on the T-24/ADM cells, lower accumalation of the drug caused by decreased uptake and increaced active efflux were observed. The cellular level of glutathione-S-transferase π was 1.8-fold higher than the parent cells and the activity of nuclear extracts of DNA topoisomerase Ⅱ for T-24/ADM assayed by decatenation of kinetoplast DNA was lower, about one-half that of the T-24 parent. Confocal laser microscopy revealed the difference in intracellular distribution of ADM in T-24/ADM; in particular, the accumlation of the drug in the nucleus decreased. Additionally western blot analysis showed an enhanced expression of multidrug resistance-associated protein (MRP) in the T-24/ADM cells. This resistant cell may be used as an experimantal system to elucidate the mechanisum of ADM resistance and also as a model for developing new chemotherapeutic strategies against multi-drug resistant bladder cancer. en-copyright= kn-copyright= en-aut-name=AkebiNaoki en-aut-sei=Akebi en-aut-mei=Naoki kn-aut-name=野比直樹 kn-aut-sei=野比 kn-aut-mei=直樹 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部泌尿器科学教室 en-keyword=adriamycin resistance kn-keyword=adriamycin resistance en-keyword=human bladder cancer cell line kn-keyword=human bladder cancer cell line en-keyword=multidrug resistance kn-keyword=multidrug resistance END start-ver=1.4 cd-journal=joma no-vol=5 cd-vols= no-issue= article-no= start-page=95 end-page=98 dt-received= dt-revised= dt-accepted= dt-pub-year=1995 dt-pub=19950131 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Oyygen uptake of adriamycin resistant cells of Ehrlich ascites tumor kn-title=アドリアマイシン耐性細胞の酸素呼吸 en-subtitle= kn-subtitle= en-abstract=Adriamycin-resistant cells of Ehrlich ascites tumor cells were established in our laboratory. Using electron microscope, the area of mitochondria (MT) per cytoplasm of ADR-resistant cells were measured with planimeter. The values of wild-type cells, 1μg/ml ADR-resistant cells and 10μg/ml ADR-resistant cells were 39.3, 51.8 and 57.7 μ(2) per 1,000 μ(2) of cytoplasm, respectively. Oxygen consumption of 1 μg/ml ADR-resistant cells and 10 μg/ml ADR-resistant cells were 1.45-fold and 1.49-fold compared to that of wild-type cells, respectively. These results indicate that ADR-resistant cells require more energy to work efflux pump than wild-type cells. kn-abstract=エールリッヒ腹水癌細胞を用いアドリアマイシンに対する耐性細胞（ADR耐性細胞）を樹立した。電子顕微鏡を用い撮影写真から細胞質当たりのミトコンドリア（MT）の割合を面積比で求めた。親株に比較して1μg/ml ADR耐性細胞では1.32倍、10μg/ml ADR耐性細胞では1.47倍であった。これらの細胞の呼吸を測定した。耐性細胞の内発呼吸は親株に比較して増加していた。1μg/ml ADR耐性細胞では1.45倍、10μg/ml ADR耐性細胞では1.49倍であり、MTの増加量とほぼ同じ割合であった。これらのことから、細胞が耐性になるとエネルギー消費が高まるために細胞内MTが増加し、その結果呼吸（酸素消費）が増加することが推察された。 en-copyright= kn-copyright= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name=川﨑祥二 kn-aut-sei=川﨑 kn-aut-mei=祥二 aut-affil-num=1 ORCID= en-aut-name=NomuraTakako en-aut-sei=Nomura en-aut-mei=Takako kn-aut-name=野村貴子 kn-aut-sei=野村 kn-aut-mei=貴子 aut-affil-num=2 ORCID= en-aut-name=MatsuuraJunko en-aut-sei=Matsuura en-aut-mei=Junko kn-aut-name=松浦順子 kn-aut-sei=松浦 kn-aut-mei=順子 aut-affil-num=3 ORCID= en-aut-name=SasakiJunzo en-aut-sei=Sasaki en-aut-mei=Junzo kn-aut-name=佐々木順造 kn-aut-sei=佐々木 kn-aut-mei=順造 aut-affil-num=4 ORCID= en-aut-name=GaoXian Shu en-aut-sei=Gao en-aut-mei=Xian Shu kn-aut-name=高献書 kn-aut-sei=高 kn-aut-mei=献書 aut-affil-num=5 ORCID= en-aut-name=AsaumiJun-ichi en-aut-sei=Asaumi en-aut-mei=Jun-ichi kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=6 ORCID= en-aut-name=Nishikawakouji en-aut-sei=Nishikawa en-aut-mei=kouji kn-aut-name=西川光治 kn-aut-sei=西川 kn-aut-mei=光治 aut-affil-num=7 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name=平木祥夫 kn-aut-sei=平木 kn-aut-mei=祥夫 aut-affil-num=8 ORCID= en-aut-name=UtsumiKozo en-aut-sei=Utsumi en-aut-mei=Kozo kn-aut-name=内海耕慥 kn-aut-sei=内海 kn-aut-mei=耕慥 aut-affil-num=9 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医療技術短期大学部診療放射線技術学科 affil-num=2 en-affil= kn-affil=岡山大学医学部第1解剖学教室 affil-num=3 en-affil= kn-affil=岡山大学医学部第1解剖学教室 affil-num=4 en-affil= kn-affil=岡山大学医学部第1解剖学教室 affil-num=5 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=6 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=7 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=8 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=9 en-affil= kn-affil=倉敷成人病センター en-keyword=アドリアマイシン (adriamycin) kn-keyword=アドリアマイシン (adriamycin) en-keyword=多剤耐性 (multidrugs resistant) kn-keyword=多剤耐性 (multidrugs resistant) en-keyword=酸素消費 (oxygen uptake) kn-keyword=酸素消費 (oxygen uptake) en-keyword=呼吸 (respiration) kn-keyword=呼吸 (respiration) en-keyword=ミトコンドリア (mitochondria) kn-keyword=ミトコンドリア (mitochondria) END start-ver=1.4 cd-journal=joma no-vol=3 cd-vols= no-issue= article-no= start-page=81 end-page=85 dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=19930131 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Relationship between intracellular uptake of adriamycin and membrane potential in ADR resistant Ehrlich ascites tumor cells kn-title=薬剤耐性細胞におけるアドリアマイシンの細胞内取り込みと細胞膜電位差の相関 en-subtitle= kn-subtitle= en-abstract= kn-abstract=We observed adiamycin (ADR) uptake and cellular transmembrane potential [amount of intracellular fluorescence of 3,3'- (Di-n-hexyl)- 2,2'- oxacarbocyanine iodide (NK-2280)] in ADR-resistant cells established from Ehrlich ascites tumor cells (EATC) and wild type EATC. In ADR-resistant cells, ADR uptake and the cellular transmembrane potential decreased as the degree of resistance increased. 4,4'- diisothiocyanatostilbene- 2,2'- disulfonic acid (DIDS) induced markedly decreases of ADR uptake and the cellular transmembrane potential. A good correlation was observed between ADR uptake and transmembrane potential in cultured cells. en-copyright= kn-copyright= en-aut-name=AsaumiJun-ichi en-aut-sei=Asaumi en-aut-mei=Jun-ichi kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=1 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name=川崎祥二 kn-aut-sei=川崎 kn-aut-mei=祥二 aut-affil-num=2 ORCID= en-aut-name=NishikawaKoji en-aut-sei=Nishikawa en-aut-mei=Koji kn-aut-name=西川光治 kn-aut-sei=西川 kn-aut-mei=光治 aut-affil-num=3 ORCID= en-aut-name=Shu GaoXian en-aut-sei=Shu Gao en-aut-mei=Xian kn-aut-name=高献書 kn-aut-sei=高献 kn-aut-mei=書 aut-affil-num=4 ORCID= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name=黒田昌宏 kn-aut-sei=黒田 kn-aut-mei=昌宏 aut-affil-num=5 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name=平木祥夫 kn-aut-sei=平木 kn-aut-mei=祥夫 aut-affil-num=6 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=2 en-affil= kn-affil=岡山大学医療技術短期大学部診療放射線技術学科 affil-num=3 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=4 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=5 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=6 en-affil= kn-affil=岡山大学医学部放射線医学教室 en-keyword=Adriamycin kn-keyword=Adriamycin en-keyword=Cell Membrane Potential kn-keyword=Cell Membrane Potential en-keyword=Flow Cytometry kn-keyword=Flow Cytometry en-keyword=ADR-Resistant Cells kn-keyword=ADR-Resistant Cells en-keyword=DIDS kn-keyword=DIDS END start-ver=1.4 cd-journal=joma no-vol=6 cd-vols= no-issue= article-no= start-page=1 end-page=5 dt-received= dt-revised= dt-accepted= dt-pub-year=1996 dt-pub=19960229 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Measurement of intracellular pH by flow cytometry using pH sensitive fluorescence dye, and influence of hyperthermia and amiloride derivatives on the intracellular pH kn-title=蛍光pH指示薬を用いたフローサイトメトリーによる細胞内pHの測定と温熱およびアミロライド誘導体の細胞内pHへの影響 en-subtitle= kn-subtitle= en-abstract=We examined relationship between intensity of intracellular fluorescence of [2', 7'-bis-(2'-carboxyethyl) carboxyfluorescein] (BCECF) and intracellular pH in Ehrlich ascites tumor cells and their adriamycin-resistant strain, and found a good correlation between them at both strains. This suggests that changes in the intracellular pH on these strains may be obtained through measurement of intracellular fluorescence of BCECF by flow cytometry. Further, we examined influence of hyperthermia, 3, 5-diamino-6-chloro-N-(diaminomethylene)pyrazinecarboxamide (amiloride), an inhibitor of Na(+)/H(+) exchanger, and its derivative; N-amidino-3-amino-6-chloro-5-(N-ethylisopropylamino) pyrazinecarboxyamide (MH-12-43) on the intracellular pH in Ehrlich ascites tumor cells. The treatment of 0.5mM amiloride or 0.05mM MH-12-43 reduced intracellular pH at 37℃, while the more reduction was observed by the treatment at 42℃. The reduction of intracellular pH by 0.05mM MH-12-43 was more substantial than that of 0.5mM amiloride at 42℃. kn-abstract=エールリッヒ腹水癌細胞とそのアドリアマイシン耐性細胞において蛍光pH指示薬2'、7'-bis-(2-carboxyethyl) carboxyfluorescein] (BCECF) の蛍光量をフローサイトメトリーで測定することによって細胞内pHの検量曲線を作成することができた。このことより、これらの細胞においてBCECFの蛍光量で細胞内pHの変化を簡易に比較できることを示唆した。さらに、温熱、Na(+)/H(+) exchanger の阻害例であるアミロライド[3,5-diamino-6-chloro-N-(diaminomethylene) pyrazinecarboxamide]、およびアミロライド誘導隊MH-12-43[N-amidino-3-amino-6-chloro-5-(N-ethyliso-propylamino) pyrazinecarboxyamide] の細胞内pHへの影響をエールリッヒ腹水癌細胞で観察した。37℃では、0.5mMアミロライド、0.05mM MH-12-43により細胞内pHは減少し、42℃処理によりさらに減少した。42℃において、0.05mM MH-12-43による細胞内pHの減少は、0.5mMアミロライドによる減少より大きかった。 en-copyright= kn-copyright= en-aut-name=AsaumiJun-ichi en-aut-sei=Asaumi en-aut-mei=Jun-ichi kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=1 ORCID= en-aut-name=KawasakiShoji en-aut-sei=Kawasaki en-aut-mei=Shoji kn-aut-name=川崎祥二 kn-aut-sei=川崎 kn-aut-mei=祥二 aut-affil-num=2 ORCID= en-aut-name=KurodaMasahiro en-aut-sei=Kuroda en-aut-mei=Masahiro kn-aut-name=黒田昌宏 kn-aut-sei=黒田 kn-aut-mei=昌宏 aut-affil-num=3 ORCID= en-aut-name=TakedaYoshihiro en-aut-sei=Takeda en-aut-mei=Yoshihiro kn-aut-name=竹田芳弘 kn-aut-sei=竹田 kn-aut-mei=芳弘 aut-affil-num=4 ORCID= en-aut-name=HirakiYoshio en-aut-sei=Hiraki en-aut-mei=Yoshio kn-aut-name=平木祥夫 kn-aut-sei=平木 kn-aut-mei=祥夫 aut-affil-num=5 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=2 en-affil= kn-affil=岡山大学医療技術短期大学部診療放射線技術学科 affil-num=3 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=4 en-affil= kn-affil=岡山大学医学部放射線医学教室 affil-num=5 en-affil= kn-affil=岡山大学医学部放射線医学教室 en-keyword=BCECF kn-keyword=BCECF en-keyword=細胞内pH (Intracellular pH) kn-keyword=細胞内pH (Intracellular pH) en-keyword=フローサイトメトリー (Flow Cytometry) kn-keyword=フローサイトメトリー (Flow Cytometry) en-keyword=アミロライド (Amiloride) kn-keyword=アミロライド (Amiloride) en-keyword=MH-12-43 kn-keyword=MH-12-43 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2004 dt-pub=20040331 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=セファランチンはアドリアマイシン耐性細胞SaOS2-AR,SaOS2 F-ARのアドリアマイシンによるアポトーシスを相乗的に増強することにより感受性を増強する kn-title=Cepharanthin enhances adriamycin sensitivity by synergistically accelerating apoptosis for adriamycin-resistant osteosarcoma cell lines, SaOS2-AR and SaOS2 F-AR en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=KatsuiKuniaki en-aut-sei=Katsui en-aut-mei=Kuniaki kn-aut-name=勝井邦彰 kn-aut-sei=勝井 kn-aut-mei=邦彰 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1986 dt-pub=19860930 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=悪性リンパ腫の治療に関する研究 第1編 化学療法不応例および再発例に対する adriamycin, vincristine, ifosfamide および prednisolone 併用(AVIP)療法 第2編 悪性リンパ腫治療における骨髄生検の意義 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=林恭一 kn-aut-sei=林 kn-aut-mei=恭一 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1993 dt-pub=19930930 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=種々の耐性機構を示すアドリアマイシン耐性ヒト肺小細胞癌株の樹立 kn-title=Establishment of an Adriamycin-Resistant Subline of Human Small Cell Lung Cancer Showing Multifactorial Mechanisms of Resistance en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=KiuraKatsuyuki en-aut-sei=Kiura en-aut-mei=Katsuyuki kn-aut-name=木浦勝行 kn-aut-sei=木浦 kn-aut-mei=勝行 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2001 dt-pub=20010325 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Adriamycin耐性ヒト膀胱癌培養細胞株の樹立と耐性機序に関する研究 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=明比直樹 kn-aut-sei=明比 kn-aut-mei=直樹 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1978 dt-pub=19781231 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=膀胱腫瘍に対するAdriamycinの膀胱腔内注入療法 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=尾崎雄治郎 kn-aut-sei=尾崎 kn-aut-mei=雄治郎 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1989 dt-pub=19890328 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Ehrlich 腹水癌細胞の薬剤耐性細胞における温熱による Adriamycin の効果増強とその修飾 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=柏谷尚子 kn-aut-sei=柏谷 kn-aut-mei=尚子 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1986 dt-pub=19860331 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=膀胱腫瘍に対する 4'-epi-Adriamycin の膀胱腔内注入療法に関する基礎的研究 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=津島知靖 kn-aut-sei=津島 kn-aut-mei=知靖 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1995 dt-pub=19950630 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=細胞外pH変化に伴う adriamycin の細胞内蓄積量に対する hyperthemia および cepharanthin の効果 kn-title=Effects of hyperthermia and cepharanthin on adriamycin accumulation with changes in extracellular pH en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=浅海淳一 kn-aut-sei=浅海 kn-aut-mei=淳一 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1999 dt-pub=19991231 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=アドリアマイシンの細胞内蓄積量における細胞外イオン濃度の影響 kn-title=Influence of Extracellular Ion Concentration on the Intracellular Accumulation of Adriamycin en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=西川光治 kn-aut-sei=西川 kn-aut-mei=光治 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1989 dt-pub=19890328 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Adriamycin の殺細胞効果の加温および Cepharanthine による修飾 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=水田昭文 kn-aut-sei=水田 kn-aut-mei=昭文 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1986 dt-pub=19860331 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Adriamycinによる腹腔滲出細胞(主にマクロフｧージ)の抗腫瘍性について en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=森岡栄 kn-aut-sei=森岡 kn-aut-mei=栄 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1985 dt-pub=19850630 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=悪性リンパ腫の治療に関する研究 第1編 非ホジキンリンパ腫における adriamycin, vincristine, ifosfamideおよびprednisolone 併用療法の検討 第2編 adriamycin の心毒性に関する研究 悪性リンパ腫症例を中心に en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=上岡博 kn-aut-sei=上岡 kn-aut-mei=博 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1997 dt-pub=19970930 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=アドリアマイシン耐性肺小細胞癌細胞株に対する葉酸代謝拮抗剤の殺細胞効果 kn-title=Growth Inhibitory Effects of Antifolates against an Adriamycin- Resistant Human Small Cell Lung Cancer Cell Line en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=松尾圭祐 kn-aut-sei=松尾 kn-aut-mei=圭祐 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1992 dt-pub=19920328 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=肺小細胞癌の化学療法に関する研究 第1編 Adriamycin 耐性ヒト肺小細胞癌細胞株の耐性解除に関する検討 第2編 肺小細胞癌完全寛解例における再発様式の検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=山下英敏 kn-aut-sei=山下 kn-aut-mei=英敏 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1995 dt-pub=19950930 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=癌遺伝子を導入したNIH3T3細胞のADRIAMYCINに対する感受性に関する研究 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=高献書 kn-aut-sei=高 kn-aut-mei=献書 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1998 dt-pub=19980325 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=DNAトポイソメラーゼⅡα のメッセンジャーRNAに対するアンチセンスオリゴDNA処理による培養ヒトグリオーマ細胞のエトポシドおよびアドリアマイシン耐性の誘導 kn-title=Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomeraseⅡα en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=栗山充夫 kn-aut-sei=栗山 kn-aut-mei=充夫 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1988 dt-pub=19880630 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=ヒト大腸癌培養細胞株RPMI4788) に対する in vitro およびヌードマウスにおけるヒト遺伝子組換え型インターフｪロンーγの単独ならびにアドリアマイシンとの併用効果 kn-title=Antitumor effect of human recombinant interferon-γ alone and in combination with adriamycin on a human colon cancer cell line (RPMI4788) in vitro and in nude mice. en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=近藤秀則 kn-aut-sei=近藤 kn-aut-mei=秀則 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1986 dt-pub=19860630 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=肺小細胞癌における抗癌剤耐性に関する研究 第1編 アドリアマイシン耐性ヒト肺小細胞癌細胞株の樹立とその性状) 第2編 アドリアマイシン耐性ヒト肺小細胞癌細胞株の in vitro における交叉耐性の検討) kn-title=第1編 Establishment and characterization of an adriamycin-resistant subline of human small cell lung cancer cells 第2編 In vitro chemosensitivity and radiosensitivity of an adriamycin resistant subline of human small cell lung cancer cells en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=宮本宏明 kn-aut-sei=宮本 kn-aut-mei=宏明 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1988 dt-pub=19880331 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=悪性リンパ腫の診断と治療に関する研究 第1編 悪性リンパ腫の診断における腹部超音波検査法に関する検討 第2編 びまん性大細胞型非ホジキンリンパ腫における Adriamycin を含む多剤併用療法の有用性に関する検討 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=吉田光雄 kn-aut-sei=吉田 kn-aut-mei=光雄 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1990 dt-pub=19900331 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Ehrlich 腹水癌細胞及び Adriamycin 耐性細胞の細胞内ミトコンドリア活性 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=岡崎良夫 kn-aut-sei=岡崎 kn-aut-mei=良夫 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2001 dt-pub=20010325 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=ドキソルビシン(アドリアマイシン)封入リポソーム腫瘍内投与は腫瘍増殖を抑制し､延命効果を示し､かつ局所および全身の副作用をもたらさない kn-title=INTRA-TUMORAL INJECTION OF DOXORUBICIN (ADRIAMYCIN) ENCAPSULATED IN LIPOSOME INHIBITS TUMOR GROWTH, PROLONGS SURVIVAL TIME AND IS NOT ASSOCIATED WITH LOCAL OR SYSTEMIC SIDE EFFECTS en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=井谷史嗣 kn-aut-sei=井谷 kn-aut-mei=史嗣 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1990 dt-pub=19900331 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Ehrlich 腹水癌細胞における Adriamycin 耐性とその克服に関する研究 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=井上信浩 kn-aut-sei=井上 kn-aut-mei=信浩 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学 END